Queensland

Caroline Salom, Rebecca Ness and Rosa Alati

QUEENSLAND DRUG TRENDS 2017

Findings from the

Illicit Drug Reporting System (IDRS)

Australian Drug Trends Series No. 189

QUEENSLAND DRUG TRENDS 2017:

findings from the Illicit Drug Reporting System (IDRS)

Caroline Salom, Rebecca Ness and Rosa Alati

Institute for Social Science Research, The University of Queensland

Australian Drug Trends Series No. 189

ISBN 978-0-7334-3802-8

Suggested citation: Salom CL, Ness R and Alati R (2017). Queensland Drug Trends 2017. *Findings from the Illicit Drug Reporting System (IDRS)*. Australian Drug Trend Series No.189. Sydney National Drug and Alcohol Research Centre, UNSW Australia.

Please note that as with all statistical reports there is the potential for minor revisions to data in this report over its life. Please refer to the online version at www.ndarc.med.unsw.edu.au

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

ACKNOWLEDGEMENTS

The 2017 Illicit Drug Reporting System (IDRS) was supported by funding from the Australian Government Department of Health under the Substance Misuse Prevention and Service Improvement Grants Fund. Our thanks to the Australian Government Department of Health for their continued assistance and support throughout the year.

The IDRS is co-ordinated by the National Drug and Alcohol Research Centre (NDARC), University of New South Wales, and sincere thanks go to our colleagues at NDARC for their continued support, professionalism and collegiality:

- Associate Professor Lucy Burns, Chief Investigator
- Dr Courtney Breen, Acting Manager of Drug Trends
- Jennifer Stafford and Rachel Sutherland, National Coordinators

The Queensland component of the IDRS is conducted by the Institute for Social Science Research, The University of Queensland. The success of the Queensland IDRS depends upon the continuing support and co-operation of a large number of stakeholders. In particular, our thanks to:

- survey participants for sharing their experiences and perceptions with us
- staff at Needle and Syringe Programs (NSPs) in Queensland whose assistance, co-operation, and generosity over the years continues to make data collection for the project possible:
    - Brisbane Harm Reduction Centre at Biala
    - Queensland Injector's Health Network (QuIHN)—Burleigh Heads NSP and Bowen Hills NSP
- interviewers Catherine Daly, Megan Garrett, Susan Beck and Camila Couto e Cruz
- individuals from the health, law enforcement, and entertainment sectors for freely giving your time and knowledge as key experts
- health and law enforcement agencies for kindly providing indicator data.

ABBREVIATIONS

ABS	Australian Bureau of Statistics
ACIC	Australian Criminal Intelligence Commission
ACBPS	Australian Customs and Border Protection Service
ADIS	Alcohol and Drug Information Service
AFP	Australian Federal Police
AIHW	Australian Institute of Health and Welfare
ANSP	Australian Needle and Syringe Program
AOD	Alcohol and other drug(s)
ATODS	Alcohol Tobacco and Other Drug Services
ATS	Amphetamine-type stimulant
AUDIT-C	Alcohol Use Disorders Identification Test–Consumption
CPR	Cardio pulmonary resuscitation
DSM-IV	Diagnostic and Statistical Manual of Mental Disorders IV
EDRS	Ecstasy and related Drugs Reporting System
GP	General practitioner
HCV	Hepatitis C virus
IDRS	Illicit Drug Reporting System
K10	Kessler Psychological Distress Scale
LSD	Lysergic acid diethylamide
MDMA	3,4-methylenedioxymethylamphetamine (‘ecstasy’)
NDARC	National Drug and Alcohol Research Centre
NDSHS	National Drug Strategy Household Survey
NSP	Needle and Syringe Program(s)
PWID	People who inject drugs
OST	Opioid substitution treatment
QNSP	Queensland Needle and Syringe Program
QPS	Queensland Police Service
QuIHN	Queensland Injectors’ Health Network
SCID	Structural Clinical Interview for DSM disorders
SD	Standard deviation
SDS	Severity of Dependence Scale
SPSS	Statistical Package for the Social Sciences

GLOSSARY OF TERMS

Base	A paste form of methamphetamine
Bush	Outdoor-cultivated cannabis
Cap	Small amount, typically enough for one injection
Halfweight	0.5 gram
Hydro	Hydroponically grown cannabis
Ice	Crystalline methamphetamine
Illicit	Illegal drugs as well as pharmaceuticals originally prescribed for someone else
Indicator data	Sources of secondary data used in the IDRS (see Method section for further details
Key expert	A person participating in the key expert survey component of the IDRS (see Method section for further details)
Licit	Pharmaceuticals (e.g. methadone, buprenorphine, morphine, oxycodone, benzodiazepines, antidepressants) obtained by a prescription in the user's name. This definition does not take account of 'doctor shopping' practices; however, it differentiates between prescriptions for self as opposed to pharmaceuticals bought on the street or those prescribed to a friend or partner
Lifetime injection	Injection (typically intravenous) on at least one occasion in the participant's lifetime
Lifetime use	Use on at least one occasion in the participant's lifetime
Mean	The average
Median	The middle value of an ordered set of values
Participant	Refers to a person who participated in the Queensland IDRS survey of PWID (does not refer to key expert participants)
PWID	People who inject drugs
Point	0.1 gram; although may also be used as a term referring to an amount for one injection (similar to a 'cap' which is explained above)
Recent injection	Injected at least once in the previous six months
Recent use	Used at least once in the previous six months
Sentinel group	A surveillance group with the potential to point towards trends and harms
Speed	Powder methamphetamine
Use	Consuming a drug via one or more of the following routes of administration: injecting, smoking, snorting, or swallowing

Guide to days of use/injection in preceding six months

180 days	Daily
90 days	Every second day
24 days	Weekly
12 days	Fortnightly
6 days	Monthly

EXECUTIVE SUMMARY

The Illicit Drug Reporting System (IDRS) is a monitoring system designed to identify emerging trends in illicit drug markets that are of local and national concern. The Reporting System comprises data collected each year from three sources: interviews with a sentinel group of people who regularly inject drugs (participants); interviews with key experts; and analysis of pre-existing data related to illicit drugs.

Demographic characteristics of participants

In 2017, 103 people who injected drugs (PWID) participated in the IDRS survey in South-East Queensland. Participants were typically 43 years old, male, single, unemployed, with a long injecting history. Just over half the sample had a prison history, and nearly half reported being currently in drug treatment.

Consumption pattern results

Current drug use

Heroin remained the most common drug of choice (47%); however, ice (32%) and heroin (25%) were the two most common drugs that participants injected the most in the past month, and ice (32%) or heroin (29%) were most commonly used in participants' most recent injection. The most frequent reason given for the disparity between drug of choice and drug use continues to be availability.

Heroin

Over half the participants (55%) had used heroin in the previous six months. Median days of use in the past six months (180 days) was 24, with 3% reporting daily use.The use of homebake continued to be rare (6%).

Methamphetamine

Methamphetamines were used by 73% of the sample in the previous six months, with most (69%) reporting that ice was the methamphetamine that they had used the most. About two fifths of all participants (44%) reported methamphetamine was the drug injected most in the previous month. Median days use of methamphetamines was 24 in 180 days.

Cocaine

Although 64% of participants has used cocaine in their lifetime, recent cocaine use continued to be rare (9%) and occasional (median of 4 in 180 days).

Cannabis

Nearly all participants had used cannabis in their lifetime, with 70% reporting recent use, and 36% of these participants using daily. Use of synthetic cannabis remained rare, with 1% of participants reporting recent use.

Other opioids

The use of opioid substitution treatment (OST) drugs in the past six months was stable with 39% reporting use of methadone, 36% buprenorphine (Subutex®), and 32% buprenorphine-naloxone (Suboxone®).

Recent use of illicit (non-prescribed) OSTs was buprenorphine 25%, methadone liquid 16%, buprenorphine-naloxone 24%, and physeptone tablets 7%.

Just under one third (27%) reported recent morphine use, and about one fifth (19%) reported recent oxycodone use: use of both was predominantly illicit.

Recent use of fentanyl was reported by 9%, non-medicinal over-the-counter codeine by 11%, and other opiates (e.g. Panadeine Forte®) by 9%.

Other drugs

As in previous years, use of ecstasy (6%), hallucinogens (6%), and inhalants (2%) was low. Pharmaceutical stimulant use (e.g. dexamphetamine and methylphenidate) also continued to be rare, with 5% licit and 11% illicit.

The majority of participants (64%) had recently used benzodiazepines (licit or illicit). Recent illicit use of alprazolam was reported by 12%, and illicit use of other benzodiazepines by 30%.

Most of the participants (89%) were smokers, but two fifths (43%) reported abstinence from alcohol in the previous six months. Among those who did drink, about a third (31%) scored ≥5 on the AUDIT-C, indicating the need for further assessment.

Drug market: Price, purity, availability and purchasing patterns

Heroin

There has been little movement on heroin prices since reporting began in 2000. The median price of a cap/point has been constant at $50, and the median price of the most common purchase weight—a quarter gram—has been $100 since 2008. Ratings of purity varied, and availability was mostly considered to be stable ~~easy or very easy~~.

Methamphetamine

Participants paid a median price of $50 for a point of ice, speed, or base. Purity was most commonly reported as high for ice (35%), medium for speed (36%), and medium for base (60%). Availability was reported as easy or very easy for ice (91%) and speed (76%), but reports were more varied for base.

Cocaine

The three reports on the cocaine market varied. The single respondent who reported on the price of their last purchase paid $20 for one gram.

Cannabis

Price was mostly reported as stable for hydro and bush: median price of a quarter ounce of hydro was $90 and bush was $70. Potency was generally rated as high for hydro and medium for bush. Hydro was readily available but bush was less so with 50% reporting it as difficult or very difficult to obtain.

OST drugs

The three reports on the price of illicit methadone varied ($0.45, $1, $1.75 per mL).

Illicit buprenorphine was most commonly purchased at a median price of $40 for 8 mg.

Reports about the illicit buprenorphine-naloxone market were mainly about film (rather than tablets). The median price of 8 mg film was $20.

Morphine

Price of morphine was mostly considered to be stable with the median price for 100 mg of MS Contin® being $50 and Kapanol being $40. Morphine was generally reported as easy (32%) or difficult (37%) and over half (56%) sourced it from a friend.

Oxycodone

No clear indication of the oxycodone market was obtained due to the small number of respondents. The price for 80 mg of Oxycontin Purdue® ranged from $40 to $80, and 80 mg of generic controlled-release oxycodone ranged from $40 to $50.

Benzodiazepine

No clear indication of the market was obtained due to only ~~three~~ seven respondents.

Other drugs

No clear indication of the fentanyl or LSD market was obtained due to the small number of respondents and little consensus.

Health-related trends associated with drug use

Overdose and drug-related fatalities

Among participants who had used heroin in their lifetime, a little less than half (45%) had accidently overdosed on it at some time. Of these, nine participants had overdosed in the preceding year. Very small numbers of participants reported ever overdosing on morphine, methadone, or oxycodone.

Nearly a fifth (16%) of all participants had accidently overdosed on another type of drug in their lifetime.

Drug treatment

Over half of the participants (57%) were currently in drug treatment, mainly OST.

Injecting risk behaviours

A small proportion of participants reported sharing needles: 9% had recently borrowed a used needle and 11% had recently lent a used needle. Sharing of other equipment (mainly spoons/mixing containers) was more common (20%).

One third re-used one of their own needles at least once in the previous month.

Opioid and stimulant dependence

Of those who had recently used opioids, 61% had a score on the Severity of Dependence Scale (SDS) indicative of dependence.

Of those who had recently used stimulants, 50% had a score on the SDS indicative of dependence.

Psychological distress

Fourty-four per cent of participants self-reported a mental health problem, with the most common problems continuing to be depression and anxiety.

Self-reported general health status

Two-in-five considered their general health to be fair or poor.

Naloxone program and distribution

Most participants (77%) had heard of naloxone, but only 37% had heard of the take-home program, and only 25% had heard about its rescheduling.

Driving while under the influence of alcohol or drugs

Of those who had driven in the past six months, 10% reported driving while over the legal limit of alcohol, and 67% reported driving within three hours of taking illicit or non-prescribed drugs.

Trends in law enforcement associated with drug use

Reports of criminal activity

Half of the participants (50%) reported criminal involvement in the previous month. As in previous years, dealing and property crime were most often reported.

Arrests

Forty per cent of participants reported having been arrested in the previous 12 months. The most common offences were use/possession of drugs and property crime (34% each)

Expenditure on illicit drugs

Less than half of the sample (47%) reported spending money on illicit drugs the day before—a median of $87.5.

Special topics of interest

Blood donations

Ten participants reported having ever having given blood, and four of these had commenced injecting drugs prior to donating blood.

Unfair treatment

The majority of respondents reported some level of unfair treatment in the previous 12 months, most commonly by the police and when getting help for physical health problems.

1 INTRODUCTION

The Illicit Drug Reporting System (IDRS) serves as a strategic early-warning system for emerging trends and patterns in illicit drug use and associated harms. The IDRS has been conducted annually in every state and territory of Australia since 2000, and is supported by funding from the Australian Government Department of Health. The IDRS focuses primarily on four illicit drugs: heroin, amphetamines, cocaine, and cannabis but also monitors trends in other drug use and drug-related harms.

An important aim of the IDRS is to disseminate its findings in a timely fashion, highlighting current issues that require further attention rather than providing a more protracted, in-depth analysis of available data. Each year, key findings from the states and territories are presented at conferences, and the final jurisdictional reports are published by the National Drug and Alcohol Research Centre (NDARC) early the following year. Additionally, NDARC produces an annual national report and, in collaboration with jurisdictional researchers, quarterly Drug Trends bulletins highlighting issues of particular relevance. Selected findings from the IDRS are also published in peer-reviewed journals. Reports and other publications are available at www.ndarc.med.unsw.edu.au.

Data for the IDRS come from three complementary sources: (a) a survey of PWID; (b) structured interviews with key experts within the drug and alcohol sector; and (c) pre-existing data sets related to illicit drugs. By triangulating information from these three sources, the IDRS aims to increase confidence in the reliability and validity of its findings.

The PWID survey component of the IDRS has been conducted in Queensland since 2000, and with each passing year the value of the data set grows. Apparent trends from one year to the next can increasingly be interpreted within a broader historical context, and long-term trends in drug use and associated harms can be identified. Along with other complementary monitoring systems, such as the national Ecstasy and related Drugs Reporting System (EDRS) and the Australian Needle and Syringe Program (ANSP) survey, the IDRS helps to paint a contextualised picture of drug use and drug-related issues in Australia.

1.1 Study aims

As in previous years, the aims of the 2017 Queensland IDRS were to:

- document the price, purity, and availability of heroin, methamphetamines, cocaine, cannabis and other drugs in Queensland
- identify, assess, and report on emerging trends in illicit drug use and associated harms.

2 METHOD

The IDRS maximises the reliability of its findings by presenting information from three complementary sources:

- structured interviews with PWID (participants)
- semi-structured interviews with key experts who are involved with the illicit drug sector
- recent indicator data collected from a variety of sources.

Participants gave informed consent prior to interview, and the information they provided has been de-identified.

Comparability across years and jurisdictions is maintained by the continued use of the same survey instruments and data sets nationwide, with minor adjustments made to the study methodology each year in accordance with developments and trends in illicit drug markets.

2.1 Survey of people who regularly inject drugs

During June and July 2016, 91 IDRS participants were individually interviewed face-to-face. Participants were PWID aged 17 years or older who had injected an illicit drug at least monthly in the previous six months, and had lived in South-East Queensland for the previous 12 months. Participants were recruited and interviewed at three Needle and Syringe Program (NSP) sites located in Brisbane and the Gold Coast.

Participants provide a sentinel group of people who regularly inject drugs rather than a representative sample of all those who regularly inject drugs.

The interview schedule was administered by trained research staff in a private room at the NSP sites. The interviews took approximately one hour to complete and participants were reimbursed $40 for their time and travel expenses. The 2016 IDRS questionnaire contained sections on:

1. participant socio-demographic characteristics
2. drug use history
3. the price, purity, availability, and purchasing patterns of illicit drugs
4. criminal involvement
5. risk-taking behaviour
6. psychological and physical health
7. general trends.

Ethical approval was obtained from the Human Research Ethics Committee at: the University of New South Wales; The University of Queensland; and Metro North and South, Queensland Health.

2.2 Survey of key experts

During August through to November 2016, eleven professionals or professional groups working in the alcohol and other drugs (AOD) sector were interviewed as key experts for the Queensland IDRS. Key experts are individuals working in the health or law enforcement sectors who are equipped to provide information on trends and patterns in illicit drug use and

associated harms due to being in regular contact with PWID or having considerable knowledge of manufacture, importation, supply, and seizure of illicit drugs.

In 2016, eight of the key experts were from the health sector and three were from law enforcement. Key experts included NSP workers, AOD nurses, staff of drug treatment agencies, researchers, outreach workers, youth workers, forensic chemists, and law enforcement and intelligence officers.

Key expert interviews were conducted face-to-face or over the telephone. Interviews took approximately 45 minutes to complete and included a range of open-ended and closed-ended questions. Questions were about the main problematic drugs, the resulting issues (health and legal), price/purity/availability of problematic drugs, and any subsequent recommendations. Responses to interview questions were analysed thematically according to recurring issues and type of drugs.

2.3 Other indicators

Secondary data was also collected to corroborate data from those who regularly inject drugs and from key experts. The following indicator data sources were used in the report:

- Australian Bureau of Statistics (ABS): National Health Survey data
- Australian Criminal Intelligence Commission (ACIC): total weight and number of drugs seized in Queensland by Queensland Police Service (QPS) and the Australian Federal Police (AFP); QPS clandestine laboratory detections and drug-related arrests; total weight and number of drugs seized at the Australian border by the Australian Customs & Border Protection Service (ACBPS)
- Australian Institute of Health and Welfare (AIHW): Queensland pharmacotherapy client registrations
- Queensland Needle and Syringe Program (QNSP): syringes provided by QNSP to NSP sites and chemists in Queensland.

2.4 Data analysis

Participant survey results were analysed using IBM SPSS Statistics, Version 22. Standard frequencies were calculated (column percentages may not add up to 100% due to rounding), and tests for significant differences between 2015 and 2016 data were conducted for drug of choice, last drug injected, drug injected most often in the past month, and use of the major drug types. These differences were calculated using the N-1 chi-squared test (www.medcalc.org/calc/comparison_of_proportions.php). Differences in days of use for the main drugs were calculated using the Mann-Whitney U test. Only test results that were statistically significant at $P < 0.05$ have been reported.

3 DEMOGRAPHICS

KEY POINTS

- **Mean age:** 41 years (range 22–65)
- **Median injecting history:** 21 years (range 1–47)
- Other characteristics of participants were similar to previous years: likely to be unemployed, male, and single; with just over half with a prison history, and almost half currently in treatment.

3.1 Overview of the IDRS participant sample

The demographic characteristics of the sample of 103 PWID from South-East Queensland were similar to those in 2016 (Table 1). Participants were typically 43 years old, male, single, and unemployed.

Table 1: Demographic characteristics, 2016 and 2017

	2016 N = 91	2017 N = 103
Age (mean, range)	41 (22–65)	**43 (22-69)**
Sex (% male)	74	**75**
Aboriginal and/or Torres Strait Islander (%)	19	**16**
Sexual identity (%)		
Heterosexual	88	**85**
Gay male	3	**3**
Lesbian	0	**-**
Bisexual	8	**12**
Other	1	**1**
Relationship status (%)		
Married / de facto	8	**17**
Partner	18	**20**
Single	60	**58**
Separated	7	**3**
Divorced	3	**1**
Widowed	4	**1**
Other	–	**-**
Highest school grade completed (mean)	10	**10**

	2016 N = 91	2017 N = 103
Course completed post-school (%)		
None	41	**45**
Trade/technical	54	**47**
University/college	6	**9**
Accommodation (%)		
Own home (including renting)	56	**61**
Parents'/family home	7	**4**
Boarding house/hostel	14	**13**
Shelter/refuge	–	**3**
Drug treatment residence (e.g. TC)	1	**-**
No fixed address	12	**18**
Other	7	**1.9**
Unemployed (%)	84	**84**
Main income from government pension, allowance or benefit (%)	92	**85**
Mean income per week ($)	(n = 89) 441	**(n = 101)** **421**
Prison history	55	**-**
Currently in drug treatment[a]	46	**59**
Opioid treatment in the past year	44	**54**

[a] Refers to any form of drug treatment (e.g. pharmacotherapy, counselling, detoxification)
Source: Queensland IDRS PWID interviews

3.1.1 Injecting history

A corollary of the increasing age of participants is that many have long injecting drug histories. The median injecting history (i.e. period since first injection) was 21 years (range 1–47).

3.1.2 Queensland Minimum Data Set for Needle and Syringe Programs (QMDS-NSP)

The 2015 QMDS-NSP (Queensland Health 2016) showed that NSP clients in Queensland had a mean age of 38 years, with 35–39 years being the most common age group. Of the 183,839 service occasions, 72% were male clients and 24% were female clients (3% missing data). Ten per cent of clients identified as an Aboriginal and/or Torres Strait Islander person; though it was noted this may be an under-representation due to missing data.

4 CONSUMPTION PATTERNS

KEY POINTS

- **Most common**
  - **first drug injected:** speed (51%) and heroin (31%)
  - **drug of choice:** heroin (47%) and ice (18%)
  - **drug injected the most in the preceding month:** ice (32%) and heroin (25%)
  - **last drug injected:** ice (32%) and heroin (29%)
- **Injected at least once per day:** 17%

4.1 Current drug use

Overall, the pattern of drug use in 2017 was similar to 2016 (Table 2). Although heroin remained the most common drug of choice, speed (methamphetamine powder) was the most common drug to be injected first, and ice (crystalline methamphetamine) was injected most often in the past month and was the last drug injected.

Table 2: Drug use patterns, 2016 and 2017

	2016 N = 91	**2017 N = 103**
Age first injection (mean years, range)	19 (8–33)	**20 (12-48)**
First drug injected (%)		
Methamphetamine (any form)	(54)	**(60)**
Speed	44	**51**
Base	7	**1**
Ice	3	**7**
Heroin	40	**31**
Morphine	1	**1**
Cocaine	1	**1**
Opioid substitution therapy (OST) drug[a]	0	**-**
Other	4	**3**
Drug of choice (%)		
Heroin	51	**47**
Methamphetamine (any form)	(23)	**(28)**
Speed	10	**8**
Base	2	**2**
Ice	11	**18**
Cannabis	8	**2**

	2016 N = 91	2017 N = 103
Morphine	11	**7**
Cocaine	0	**2**
Buprenorphine	0	**1**
Buprenorphine-naloxone	2	**2**
Methadone	2	**4**
Other	2	**4**
Drug injected most often in past month (%)		
Heroin	30	**25**
Methamphetamine (any form)	(33)	**(44)**
Speed	0	**10**
Base	1	**1**
Ice	32	**32**
Morphine	13	**9**
Opioid substitution therapy (OST) drug[a]	15	**18**
Oxycodone	2	**2**
Other/have not injected in past month	4	**3**
Last drug injected (%)		
Heroin	28	**29**
Methamphetamine (any form)	(30)	**(42)**
Speed	0	**8**
Base	0	**1**
Ice	30	**32**
Morphine	12	**8**
Opioid substitution therapy (OST) drug[a]	23↑	**18**
Oxycodone	2	**2**
Other drug	4	**2**
Frequency of injecting in past month (%)		
Not in last month	1	**2**
Weekly or less	14	**27**
More than weekly, but less than daily	47	**32**
Once per day	9	**17**
2–3 times a day	23	**15**
>3 times a day	6	**8**

[a]methadone, buprenorphine, buprenorphine-naloxone
Arrow symbol signifies a significant difference $P < 0.05$.
Source: Queensland IDRS PWID interviews

4.1.1. Drug of choice

Drug of choice followed a similar pattern to previous years (Table 2), with just under half of participants (47%) nominating heroin. The remainder nominated a variety of drugs, with only 18% choosing ice.

4.1.2. Drug last injected and injected most often in the past month

Even though heroin was the drug of choice for just under half of participants, ice was the drug most likely to have been last injected (32%) and to have been most often injected in the past month (32%) (Table 2). The main reason given for there being a difference between drug of choice and drug used continues to be availability (Figure 1).

Figure 1: Reason for disparity between drug of choice and drug used most often, 2017



Source: Queensland IDRS PWID interviews

4.1.3 Trends over time

Heroin has remained the top drug of choice, followed by methamphetamines (Figure 2).

Figure 2: Top two drugs of choice, 2007 to 2017



Source: Queensland IDRS PWID interviews

As Figure 3 shows, during the last decade, heroin was consistently the drug injected most often in the previous month until 2015 when methamphetamine became the drug most often injected (33% in 2015 and 2016, and 32% in 2017). The form of methamphetamine in 2017 was mainly ice (32%), with only one participant injecting base the most often. The third most commonly injected drug continued to be morphine (9% in 2017).

Figure 3: Drug injected most often in previous month, 2007 to 2017



Source: Queensland IDRS PWID interviews

4.1.4 Polydrug use

Polydrug use continued to be nearly universal, with most participants using tobacco and high percentages using methamphetamines, alcohol, cannabis, and heroin (Figure 4).

Figure 4: Drugs used in last six months, 2017



Note: 'Any' refers to both licit and illicit. 'Use' refers to any form of administration and does not necessarily imply injection.
Source: Queensland IDRS PWID interviews

4.1.5 Forms of drugs used in last six months

Table 3 presents information about use of the main drug types: when they were used (ever, previous six months), the sub-types used, the mode of administration, and the frequency.

Table 3: Drug use history, 2017

	Used			Injected			Other routes of administration used in the last 6 months		
							Smoked	Snorted	Swallowed
N = 103	Ever %	6 months[a] %	Days[b] (180)	Ever %	6 months[a] %	Days[b] (180)	%	%	%
Heroin	88	55	24	88	54	24	4	0	1
Homebake	41	6	4	39	5	4	0	0	0
Any heroin	88	55	-	88	54	23	-	-	-
Methadone *licit*	55	23	180	33	12	48			21
Methadone *illicit*	55	16	4	48	14	4			3
Physeptone *licit*	17	1	2	7	1	2	0	0	0
Physeptone *illicit*	29	7	20	25	7	20	0	0	1
Any methadone	78	39	90	69	26	20	-	-	-
BPN (Subutex®) *licit*	48	19	180	30	16	72	1	2	14
illicit	53	25	7	51	24	8	0	1	7
Any BPN	72	36	60	56	32	8	-	-	-
BPNX (Suboxone®) *licit*	46	18	180	28	13	60	0	0	13
illicit	46	24	8	38	20	12	20	0	0
Any BPNX	63	32	42	42	24	28	-	-	-
Morphine *licit*	36	6	7	24	6	7	0	0	0
Morphine *illicit*	66	26	10	59	23	10	0	0	5
Any morphine	70	27	12	62	25	12	-	-	-
Generic oxycodone *licit*	16	2	7	11	2	7	0	0	0
Generic oxycodone *illicit*	41	11	5	35	7	3	0	1	4
Any generic oxycodone	44	12	-	36	8		-	-	-

	Used			Injected			Other routes of administration used in the last 6 months		
							Smoked	Snorted	Swallowed
N = 103	Ever %	6 months[a] %	Days[b] (180)	Ever %	6 months[a] %	Days[b] (180)	%	%	%
OP oxycodone *licit*	4	1	5	3	1	5	0	0	0
OP oxycodone *illicit*	21	10	2	17	7	2	0	0	4
Any OP oxycodone	23	11		18	8	-	-	-	-
Other oxycodone *licit*	8	0	-	4	-	-			
Other oxycodone *illicit*	21	6	18	20	5	30	0	0	2
Any other oxycodone	21	6		20	5		-	-	-
Any oxycodone	55	19	7	48	14	7	-	-	-
Fentanyl	33	9	3	29	9	3	0	0	0
Over-counter codeine **(non-medicinal use)**	32	11	5	6	0	-	0	0	0
Other opiates	35	9	3	6	0	-	0	0	9
Speed powder	89	34	8	85	31	8	4	2	0
Amphetamine liquid	26	4	12	26	4	12			0
Base amphetamine	60	19	5	59	18	5	-	-	-
Crystal/ice	89	69	20	88	68	22	17	1	2
Any methamphetamine	96	73	-	95	73	24	-	-	-
Prescription stimulants *licit*	20	5	96	6	1	72	0	0	5
Prescription stimulants *illicit*	34	11	2	16	7	2	0	0	7
Any prescription stimulants	45	13	5	20	8	2	-	-	-
Cocaine	64.	9	4	38	3	1	0	5	1
Hallucinogens	67	6	5	11	1	1	1	0	4

	Used			Injected			Other routes of administration used in the last 6 months		
							Smoked	Snorted	Swallowed
N = 103	Ever %	6 months[a] %	Days[b] (180)	Ever %	6 months[a] %	Days[b] (180)	%	%	%
Ecstasy	64	6	5	29	1	2	0	0	6
Alprazolam *licit*	26	3	120	8	0	-	0	0	3
Alprazolam *illicit*	52	12	6	14	3	4	0	0	10
Any alprazolam	58	14		18	3	-	-	-	-
Other benzo. *licit*	70	46	108	6	0	-	1	0	45
Other benzo. *illicit*	48	30	6	4	2	1	0	0	29
Any other benzodiazepine	83	60		8	2	-	-	-	-
Any benzodiazepine	85	64	54	22	4	1	-	-	-
Seroquel *licit*	32	9	180	3	1	96			8
Seroquel *illicit*	33	7	2	2	0	-			7
Any Seroquel	55	16	130	4	1	96			-
Alcohol	94	57	24	12	1	5			57
Tobacco	98	89	180						
E-cigarette	30	12	9						
Cannabis	95	70	45				66		4
Synthetic cannabis	7	1	-				1		0
Inhalants	18	-	70						
Steroids	8	1	96	6	-	-	0	0	1
New psychoactive substances (NPS)	3	1	2	3	1	2	0	0	0

[a] in the previous six months; [b] median days used among those who have used in the previous six months (180 days)
Source: Queensland IDRS PWID interviews

4.2 Heroin

KEY POINTS

- **Recent heroin use:** 55% in the past six months
- **Daily use:** 16% of those who recently used heroin
- **Injected heroin the most in the past month:** 25%
- **Homebake:** use continued to be rare (6%)

4.2.1 Use of heroin

Most participants (88%) had used heroin in their lifetime, but 55% reported recent use (58% in 2016, Figure 5). All those who had recently used heroin reported injecting it, while 4% also reported smoking it and 1% reported swallowing it. The proportion of participants who nominated heroin as the drug injected the most was similar to 2016. Of those who had used heroin in the last six months, 9% used it daily (19% in 2015 and 9% in 2016).

Figure 5: Prevalence and frequency of heroin use, 2007 to 2017



Source: Queensland IDRS PWID interviews

In 2017, the median days of heroin use in the previous six months was 24 (n = 57, range 1–180) which was not significantly higher than in 2016 (Figure 6).

Figure 6: Median days of heroin use in last six months (180 days), 2007 to 2017



Source: Queensland IDRS PWID interviews

4.2.2 Use of heroin in the general population

The National Drug Strategy Household Survey is undertaken approximately every three years. Findings from the 2016 survey were not available at time of publication, and Table 4 presents findings only up to the 2013 survey: over 20 years the use of heroin in the general population declined from a high of 0.8 in 1998 to 0.1 in 2013.

Table 4: Heroin use among the Australian population aged 14 years and over, 1995 to 2016

	1995	1998	2001	2004	2007	2010	2013	**2016**
Last 12 months	0.4	0.8	0.2	0.2	0.2	0.2	0.1	**0.3**
Ever	1.4	2.2	1.6	1.4	1.6	1.4	1.2	**1.3**

Source: National Drug Strategy Household Survey 2016 (AIHW 2017)

4.2.2 Homebake

Homebake is a form of heroin made from pharmaceutical products and involves the extraction of diamorphine from pharmaceutical opioids such as codeine and morphine. Questions about homebake were first included in 2002 and since then reports of recent use have been low. In 2017, 6% of participants used (injected) homebake in the preceding six months on a median of 3.50 days (range 1–96 days).

4.2.3 Heroin forms used

Among recent heroin users (n = 57), 58% reported having used white/off-white heroin in the previous six months and 54% reported having used brown/beige heroin.

Table 5 presents the most commonly used form in the previous six months. As in 2016, white/off-white powder or rock was most commonly used.

Table 5: Heroin forms most used, 2017

n = 56	Heroin powder			Heroin rock		
	White/ off-white %	Brown/ beige %	Other colour %	White/ off-white %	Brown/ beige %	Other colour %
Most used in last six months	12	8	1	19	15	-

Source: Queensland IDRS PWID interviews

4.2.4 Heroin quantities used

Of those who reported their average amount used in a session in grams (n = 24), the median quantity was a 1/4 gram (range 0.12 to 1.50 grams).

Of those who reported their average amount used in a session in points (n = 30), the median quantity was 1.25 points (range 0.20 to 14 points).

4.3 Methamphetamines

KEY POINTS

- **Recent methamphetamine use:** 73%
  - **ice:** 69%
  - **speed:** 34%
  - **base:**19%
  - **liquid:** 4%
- **Injected ice the most in the last month:** 32%

4.3.1 Use of methamphetamines

Recent use of methamphetamines (includes speed, base, ice, and liquid) remained stable (Figure 7). In 2016 a third of participants reported that methamphetamine was the drug most often injected, and in 2017 the percentage of participants reporting this was 44%. Among those who had used methamphetamines in the last six months, 7% reported daily use.

Figure 7: Use of methamphetamine (in any form) in last six months, 2007 to 2016



Source: Queensland IDRS PWID interviews

4.3.2 National population data

According to the 2016 National Drug Strategy Household Survey report (AIHW 2017), 6% of Australians had used methamphetamines in their lifetime with 1.4% having used methamphetamines in the previous 12 months.

4.3.3 Methamphetamine form most used

As in previous years, data were collected about four different forms of methamphetamines: speed (powder), base, ice (crystalline), and liquid.

Source: Methamphetamine Forms compiled by Adam Churchill, Australian Customs Service, and Libby Topp, National Drug and Alcohol Research Centre

A breakdown of the various forms of methamphetamines used by survey participants over the last decade (Figure 8) shows the upward trend of ice in recent years.

Figure 8: Forms of methamphetamine used in last six months, 2007 to 2017



Source: Queensland IDRS PWID interviews

Due to the continuing low use of liquid methamphetamine in 2017, data specifically about liquid will not be presented.

4.3.4 Methamphetamine frequency of use

Among those who had recently used methamphetamines, most used ice and only a small proportion used speed and base (Figure 9).

Figure 9: Form of methamphetamine most used in last six months, 2017



Source: Queensland IDRS PWID interviews

In 2017, the median days of methamphetamine use was 24, compared with 15.5 in 2016 (Table 6). There was a significant drop ($P < 0.05$) in the median days of speed use from 5.5 (n = 24, range 1–60) in 2016 to 8 (n = 35, range 1–180) in 2017.

Table 6: Median days of methamphetamine use in last six months, 2016 and 2017

	Median days	
	2016	**2017**
Speed	5.5	**8**
Base	6	**4.50**
Ice	12	**20**
Any form[a]	15.5	**24**

[a] includes speed powder, base, ice/crystal and liquid forms

Note: Maximum number of days (i.e. daily use) = 180. Source: Queensland IDRS PWID interviews

4.3.5 Average session measures

Participants were more likely to measure the amount of methamphetamine taken in an average session in points rather than grams (Table 7). The median amount of ice (in points) used in a typical session was just over a point.

Table 7: Median amount (points and grams) used in an average session, 2017

	Speed	Base	Ice
Points	n = 27 2 (0.5–35)	n = 16 2 (1–5)	n = 59 2 (0.5–17)
Grams	n = 7 0.5 (0.1–2)	n = 4 0.5 (0.25–0.5)	n = 9 0.5 (0.1–1)

Source: Queensland IDRS PWID interviews

4.4 Cocaine

KEY POINTS

- **Recent cocaine use:** 9%
- **Lifetime use:** 73%
- **Frequency of recent use:** occasional

4.4.1 Use of cocaine

Nearly two-thirds (64%) of the sample had used cocaine in their lifetime, but only 9% reported recent use. This low level of use in the previous six months has been relatively consistent over the last 10 years (Figure 10).

Eight participants only used powder: one used crack and none used rock. Snorting was the most common route of administration (five of the nine), with four reporting snorting and one swallowing. Use was occasional (median of 1.5 days, n = 8, range 1–10) in the preceding six months (180 days).

Figure 10: Cocaine use in last six months, 2007 to 2016



Source: Queensland IDRS PWID interviews

4.4.2 National population data

The 2013 National Drug Strategy Household Survey report (AIHW 2014) shows that 8.1% of Australians reported using cocaine in their lifetime, and 2.1% in the previous 12 months.

4.5 Cannabis

KEY POINTS

- **Recent cannabis use:** 64%
- **Lifetime use:** 97%
- **Daily use:** 37% of cannabis users
- **Recent synthetic cannabis use:** 3%

4.5.1 Use of cannabis

As in previous years, nearly all participants (95%) had used cannabis in their lifetime. Over two-thirds (70%) of participants reported recent use (Figure 11), and nearly a fifth (22%) of these participants used cannabis daily. The median days of use was 45 (n = 71, range 1–180 days). Consistent with previous years, a small proportion of participants (2%) nominated cannabis as their drug of choice.

Figure 11: Prevalence and frequency of cannabis use, 2007 to 2017



Source: Queensland IDRS PWID interviews

4.5.2 National population data

According to the 2016 National Drug Strategy Household Survey report (AIHW 2017), cannabis was the most commonly used illicit drug in Australia, with 35% reporting use in their lifetime and 10.4% in the previous 12 months.

4.5.3 Cannabis forms used

Of those who reported recent cannabis use (n = 7), 83% had used hydroponic cannabis, 49% used bush (outdoor grown), and 7% used hash oil.

When asked whether they mostly used hydroponic or bush cannabis, 78% said they mostly used hydroponic and 18% said they mostly used bush.

Cones continued to be more common than joints, with the median amount used in a session being 5 cones (n = 35, range 1–35) or one joint (n = 18, range 1–9).

4.5.4 Routes of administration

The majority of respondents (66%) reported smoking cannabis. Another 4% reported swallowing.

4.5.5 Synthetic cannabis

Synthetic cannabis had been used by 7% of participants; however, only one participant had used it in the previous six months, and reported smoked it.

4.6 Other opioids

KEY POINTS

- **Methadone:** 39% recent use—23% licit and 16% illicit (non-prescribed).
- **Buprenorphine** (Subutex®)**:** 36% recent use—19% licit and 25% illicit.
- **Buprenorphine-naloxone** (Suboxone®)**:** 32% recent use—18% licit and illicit 24%.
- **Morphine:** 27% recent use—6% licit and 26% illicit.
- **Oxycodone (any):** 19% recent use of one or more forms—primarily illicit: 11% generic ,10% OP, 6% other.
- **Fentanyl:** 9% recent use: all participants reported injection and no use as a transdermal patch.
- **Over-the-counter codeine for non-medicinal purposes:**11% recent use.
- **Other opiates** (e.g. pethidine, Panadeine Forte®)**:** 9% recent use.

4.6.1 Substitution pharmacotherapy

Methadone is prescribed as a substitute drug for opioids, and is usually prescribed as a liquid preparation and commonly dosed under supervision. Physeptone tablets are less common in Australia and are usually prescribed for people in methadone treatment who are travelling or, in a minority of cases, where methadone is not tolerated. The majority of participants (78%) had used liquid methadone or physeptone tablets (licit or illicit) in their lifetime, and 39% in the previous six months.

Buprenorphine (Subutex®) was introduced as an alternative to methadone and, since 2005, buprenorphine-naloxone (Suboxone®) is widely prescribed because of its agonist/anti-agonist properties. Initially, buprenorphine and buprenorphine-naloxone were dispensed in tablet form to be dissolved under the tongue; however, since late 2011, they have been dispensed as sublingual film strips. In 2017, 72% of participants had used a form of buprenorphine and 63% a form of buprenorphine-naloxone (licit and/or illicit) in their lifetime, and 36% and 32% in the previous six months.

The pattern of use of all four substitution drugs is shown in Table 8. Methadone liquid was the most common licit form and buprenorphine and buprenorphine-naloxone were the most common illicit forms.

Table 8: Use of licit and illicit substitute drugs in last six months, 2017

	LICT (prescribed)		ILLICIT (not prescribed)	
	Used	Injected	Used	Injected
N = 103	%	%	%	%
Methadone liquid	23	12	16	14
Physeptone tablets	1	1	7	7
Buprenorphine film	19	16	25	24
Buprenorphine-naloxone film	18	13	24	20

Source: Queensland IDRS PWID interviews

Use of methadone

Over half (55%) of participants reported having been prescribed methadone at least once in their lifetime (i.e. licit use), and 55% reported illicit use at least once in their lifetime.

Sixty-nine per cent of participants reported injecting methadone (licit or illicit) in their lifetime, and 26% reported injecting it in the previous six months (Figure 12). The median days participants recently injected methadone were 3.5 (range 1–150).

Figure 12: Injected methadone (licit or illicit) in last six months, 2007 to 2017



Source: Queensland IDRS PWID interviews

Use of buprenorphine (Subutex®)

Seventy-two per cent of participants had used buprenorphine (licit or illicit) in their lifetime, with 36% having used it in the previous six months. Licit (i.e. prescribed) recent use was reported by 19% and illicit use by 25%. Of the 17 participants on a prescribed dose, sixteen reported injecting their dose. Almost all those who had recently used illicit buprenorphine injected it (24%) while 1% snorted and 7% swallowed (Figure 13). Median days injected in the previous six months was 7 (range 1–180).

Figure 13: Use and injection of illicit buprenorphine in last six months, 2007 to 2017



Source: Queensland IDRS PWID interviews

Use of buprenorphine-naloxone (Suboxone®)

Nearly two thirds of participants (63%) had ever used buprenorphine-naloxone (licit or illicit), and 32% had used it in the previous six months.

Film was more likely to be used than tablets for both licit and illicit use.

Nearly a quarter of participants reported recently using illicit buprenorphine-naloxone (tablet or film), with 20% reporting injecting it and 20% reporting smoking it in the previous six months (Figure 14).

Figure 14: Use and injection of illicit buprenorphine-naloxone (tablet or film) in last six months, 2007 to 2017



Note: Prescribing of film commenced in late 2011
Source: Queensland IDRS PWID interviews

4.6.2 Use of morphine

Seventy per cent of participants had used morphine (licit or illicit) in their lifetime, with 27% reporting morphine use (licit or illicit) in the previous six months. As in previous years, the most common brand of morphine was MS Contin®.

Licit morphine was used by 6% with 6% reporting injection (8% used and 7% injected in 2016). Median days of use was 6.50 (n = 6, range 2–180).

Illicit morphine was used by 26%, with all injecting—though 5% also swallowed (Figure 15). Illicit morphine was used on a median of 10 days in the preceding six months (n = 27, range 1–180).

Figure 15: Use and injection of illicit morphine in last six months, 2007 to 2017



Source: Queensland IDRS PWID interviews

4.6.3 Use of oxycodone

Over half of participants (55%) had used oxycodone (licit and illicit) in their lifetime and 19% in the previous six months. OxyContin® and Endone® were the most commonly used brands. Participants were asked about their consumption of three forms of oxycodone: generic, Oxycontin Purdue® (reformulated to be injection-proof), and all other forms.

Licit use in the previous six months was 2% for generic, 1% for Oxycontin Purdue®, and no licit use for all other forms.

Illicit use in the previous six months was 11% for generic, 10% for Oxycontin Purdue®, and 6% for all other forms. Nearly all reported injection with some reporting swallowing.

4.6.4 Use of fentanyl

Fentany use was similar to 2016 (Figure 16), with 33% having used in their lifetime and 9% having used recently. Of those who had recently used, none reported using prescribed

fentanyl. All injected. The median days of injection in the past six months was 3 (n = 9, range 1–72 days).

Figure 16: Use of fentanyl, 2016 and 2017



Source: Queensland IDRS PWID interviews

4.6.5 Use of over-the-counter codeine, non-medicinal purposes only

In 2017, 11% of participants had used over-the-counter codeine for non-medicinal purposes in the previous six months (21% in 2016; Figure 17). Use over lifetime was 32% compared with 26% in 2016.

Figure 17: Use of over-the-counter codeine, non-medicinal purposes only, 2016 and 2017



Source: Queensland IDRS PWID interviews

4.6.6 Use of other opiates

Lifetime use of opiates such as pethidine, Panadeine Forte®, and opium was lower at 35% (Figure 18). Recent use (9%) was predominantly licit and Panadeine Forte® was the form most commonly used. Days of use varied widely (median 3, range 1–14).

Figure 18: Use of other opiates, 2016 and 2017



Source: Queensland IDRS PWID interviews

4.7 Other drugs

KEY POINTS

- **Ecstasy:** 6% recent use; 64% lifetime use
- **Hallucinogens:** 6% recent use; 67% lifetime use
- **Benzodiazepines:** 64% had used licit and/or illicit forms in the preceding six months. Recent illicit use was alprazolam 12% and other benzodiazepines 30%.
- **Pharmaceutical stimulants** (e.g. dexamphetamine and methylphenidate)**:** recent use continued to be rare (5% licit and 11% illicit).
- **Inhalants:** use remained low, with 18% reporting lifetime use and no reports of recent use.
- **Alcohol:** 43% reported abstinence from alcohol in the previous six months. Of those who drank, 31% scored ≥5 on the AUDIT-C, indicating the need for further assessment.
- **Tobacco:** 89% recently used tobacco, with 92% of these smoking daily.

4.7.1 Ecstasy and related drugs

Although 64% of participants reported use of ecstasy (MDMA) in their lifetime, only 6% reported use in the previous 6 months (Figure 19): 6% swallowed and 1% injected.

Figure 19: Use and injection of ecstasy in last six months, 2007 to 2017



Source: Queensland IDRS PWID interviews

4.7.2 Hallucinogens

Recent hallucinogen use (LSD, mushrooms, etc.) remained low (6%); although use in lifetime was 67% (Figure 20).

Figure 20: Hallucinogen use in last six months, 2007 to 2017



Source: Queensland IDRS PWID interviews

4.7.3 Benzodiazepines

Most participants (85%) had used a form of benzodiazepine in their lifetime whether licit or illicit, and 64% had done so recently. Table 9 shows recent use of benzodiazepines, such as diazepam (Valium®, Antenex®) and oxazepam (Serapax®), and recent use of alprazolam (Xanax®, Kalma®). The pattern of licit and illicit use is consistent with previous years.

Lifetime use of licit or illicit alprazolam was reported by 58%, with 12% reporting recent use, a reduction from 2016. (Alprazolam was rescheduled as a controlled drug, Schedule 8, in February 2014).

Lifetime use of other licit or illicit benzodiazepines was reported by 83% of participants, with 60% reporting recent use. Injection of any form of benzodiazepine was rare.

Among those using any form of benzodiazepine (n = 66), 24% used daily. Median days use of alprazolam was 5.5 for illicit (n = 12, range 1–90) and 120 for licit (n = 3, range 2–180). For other benzodiazepines, median days of use was 6 for illicit (n = 30, range 1–180) and 108 for licit (n = 46, range 2–180).

Table 9: Use of licit and illicit benzodiazepines in last six months, 2016 and 2017

	Licit (prescribed)		**Illicit** (not prescribed)	
	2016 N = 91 %	**2017** **N = 103** **%**	2016 N = 98 %	**2017** **N = 103** **%**
Alprazolam	7	**3**	25	**12**
Other benzodiazepines	44	**46**	33	**30**

Source: Queensland IDRS PWID interviews

4.7.4 Pharmaceutical stimulants

As in previous years, recent use of pharmaceutical stimulants (e.g. dexamphetamine and methylphenidate) was low with 5% of participants reporting licit use and 11% reporting illicit use.

4.7.5 Inhalants

There were no reports of recent inhalent use. Lifetime use remained fairly low at 18% (Figure 21).

Figure 21: Prevalence of inhalant use, 2007 to 2017



Source: Queensland IDRS PWID interviews

4.7.6 Alcohol

Nearly all participants (94%) reported lifetime use of alcohol, with 57% reporting recent use (i.e. 43% reporting abstinence from alcohol). Injection of alcohol was rare, with 12%

reporting having injected alcohol in their lifetime and 1% in the previous six months. The median frequency of alcohol use was 24 days (range 1–180).

There tends to be a focus on young people and alcohol in the media, with little attention given to alcohol use among PWID. PWID are particularly at risk for alcohol-related harms due to high prevalence of the hepatitis C virus (HCV). Half of the participants interviewed in the Australian NSP Survey 2013 (n = 2 407) reported having HCV antibodies (Iverson, Chow, & Maher, 2014). Given that the consumption of alcohol has been found to exacerbate HCV infection and to increase the risk of both non-fatal and fatal opioid overdose and depressant overdose (Coffin et al., 2007; Darke, Duflou, & Kaye, 2007; Darke, Ross, & Hall, 1996; Schiff & Ozden, 2004), it is important to monitor risky drinking among people who inject drugs.

In recent years, participants have been asked to complete the Alcohol Use Disorders Identification Test–Consumption (AUDIT-C) as a validated measure of heavy drinking (Bush, Kivlahan, McDonell, Fihn, & Bradley, 1998). The AUDIT-C is a three-item measure, using the first three consumption questions in the AUDIT. Dawson et al (2005) reported on the validity of the AUDIT-C, finding that it was a good indicator of alcohol dependence, alcohol use disorder, and risky drinking.

Among study participants who drank alcohol in the past year, the overall mean score on the AUDIT-C was 4.5 (median 4, range 0–12) (Table 10). There was no significant sex difference: mean score was 4.46 for females (n = 19) and 4.50 for males (n = 52). According to Dawson and colleagues (2005) and Haber and colleagues' (2009) *Guidelines for the Treatment of Alcohol Problems*, a cut-off score of 5 or more indicates that further assessment is required.

One-third (31%) of participants who drank in the past year scored ≥5 on the AUDIT-C, indicating the need for further assessment (Table 9); scores were similar for males and females.

Table 10: AUDIT-C score, 2016 and 2017

	2016 n = 64	**2017** **n = 71**
Mean AUDIT-C score	5.1	**4.5**
SD (range 0–12)	3.6	**3.4**
Score of 5 or more	47%	**45%**

Source: Queensland IDRS PWID interviews

4.7.7. Tobacco use

Consistent with previous years, most participants (89%) reported recent tobacco use (Figure 22) with 92% of these respondents reporting daily smoking.

Figure 22: Tobacco use in last six months, 2007 to 2016



Source: Queensland IDRS PWID interviews

About a third of participants (30%) reported use of e-cigarettes in their lifetime, with only 12% reporting recent use. Median days used was 8.5 (n = 12, range 1–180).

5 DRUG MARKET: PRICE, PURITY, AVAILABILITY AND PURCHASING PATTERNS

This section is about the market characteristics (i.e. price, perceived purity/strength, availability, and purchasing patterns) for the main drugs of interest. Participants were asked to provide information about a drug only if they were confident that they knew about that particular market. Consequently, the number of participants providing market information about each drug varies considerably. Limited responses to some questions restricted meaningful interpretation.

5.1 Heroin market

KEY POINTS

- **Median price:** remained constant (e.g. $100 per quarter gram)
- **Purity:** most commonly reported as medium or low, with 38% reporting it as stable and 36% as increasing.
- **Availability:** nearly all reported it as easy or very easy to obtain. Purchases were most commonly made from a known dealer or friend at an agreed public location or dealer's home.

Of the entire sample (N = 103), 53 participants answered questions about the heroin market, and analysis is based on this sub-sample.

5.1.1 Heroin price

Heroin prices have remained constant with only occasional slight variance in the last decade:

Cap/point	$50 (range $40–$250, n = 26)
Quarter gram	$100 (range $50–$400, n = 18)
Half gram	$200 (range $150–$600, n = 17)
Gram	$400 (range $200–$500, n = 10)
1.7 grams (1/16 oz)	$400^ (range $350–$450, n = 2)

Note: ^ Small numbers reported; interpret with caution (n <10)

In keeping with the consistency of pricing in recent years, most respondents (n = 48, 79%) rated heroin prices as stable. Pricing was in keeping with Queensland prices reported by the Australian Criminal Intelligence Commission (2017).

5.1.2 Heroin form and purity

The current purity of heroin was most commonly rated as medium or low, with 26% rating it as high (Table 11). Over one-third (38%) considered that purity had not changed in the past six months, but another 36% considered it to be increasing. Overall, there appeared to be more ratings of high purity in 2017 than in 2016.

Table 11: Perceptions of heroin purity in last six months, 2016 and 2017

	2016 %	2017 %
Current purity	n = 50	**n = 51**
High	8	**26**
Medium	40	**41**
Low	30	**31**
Fluctuates	22	**2**
Purity change over the past six months	n = 48	**n = 47**
Increasing	17	**36**
Stable	50	**38**
Decreasing	10	**9**
Fluctuating	23	**17**

Note: Those choosing 'don't know' were excluded from analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.1.3 Heroin availability

Heroin was mostly reported to be easy or very easy to obtain (91%, n = 53). Over the last decade, heroin has generally been reported as readily available (Figure 23).

Figure 23: Current heroin availability, 2007 to 2017



Source: Queensland IDRS PWID interviews

Participants were also asked about changes in heroin availability in the preceding six months: most (90%) considered it to be stable (Table 12).

Table 12: Changes in heroin availability in last six months, 2016 and 2017

	2016 (n = 51) %	**2017 (n = 48) %**
More difficult	4	**0**
Stable	75	**90**
Easier	18	**2**
Fluctuates	4	**8**

Note: Those choosing 'don't know' were excluded from analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.1.5 Purchasing patterns of heroin

A friend was the most common person from whom the most recent purchase of heroin was made (44%; Table 13), followed bya known dealer (31%). Place of purchase was similar to 2016, with the most likely purchase place being an agreed public location (39%), followed by dealer's home (21%).

Table 13: Purchasing patterns of heroin, 2016 and 2017

	2016 %	**2017 %**
Last purchased from	n = 50	**n = 52**
Known dealer	52	**31**
Friend	34	**44**
Acquaintance	6	**17**
Unknown dealer	6	**-**
Mobile dealer	2	**2**
Street dealer	0	**6**
Place of most recent purchase	n = 50	**n = 52**
Agreed public location	50	**39**
Dealer's home	22	**21**
Home delivery	12	**19**
Friend's home	8	**17**
Street market	6	-
Acquaintance's home/other	2	**4**

Note: Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.1.6 Heroin detected at the Australian border

The number of heroin detections at the border by the Australian Customs and Border Protection Service in the financial year 2014–15 was 291 compared with 180 in 2013–14; the total weight also rose, from 119 kilograms in 2013–14 to 319 kilograms in 2014–15 (Figure 24).

Figure 24: Weight and number of heroin border seizures by the Australian Customs and Border Protection Service, 2004–05 to 2014–15



Source: Australian Criminal Intelligence Commission, 2016

5.2 Methamphetamine market

KEY POINTS

- **Median price**: $50 per point for powder, base, and ice.
- **Purity:** crystal/ice reported as mostly high and medium. Speed was most commonly rated as medium, and base was most commonly rated as medium.
- **Availability:** crystal/ice and speed were reported to be readily available; base was mostly reported as difficult (46%).

Of the entire sample (N = 103), 25 participants answered questions about the speed market, 11 about base, and 61 about ice. Analysis is based on these sub-samples.

5.2.1 Methamphetamine price

The median prices of participants' most recent purchase of each form of methamphetamine were:

Speed

Point (0.1 g)	$50 (range $25–$250, n = 20)
Halfweight (0.5 g)	$200^ (range $30–$250, n = 6)
Gram (1 g)	$350^ (range $50–$400, n = 6)

Base

Point (0.1 g)	$50^ (range $50–$50, n = 8)
Halfweight (0.5 g)	$250^ (range $200–$250, n = 5)
Gram (1 g)	$400^ (range $300–$400, n = 3)
Eightball (3.5 g)	$750^ (range$600–$900, n = 2)

Ice

Point (0.1 g)	$50 (range $50–$100, n = 48)
Halfweight (0.5 g)	$220 (range $25–$300, n = 11)
Gram (1 g)	$300 (range $50–$400, n = 12)
Eightball (3.5 g)	$775^ (range $490–1000, n = 8)

Note: ^ Small numbers reported; interpret with caution (n <10)

The price of speed, base and ice were all considered to be stable (Table 14).

Table 14: Methamphetamine price changes in last six months, 2016 and 2017

Price	Speed		Base		Ice	
	2016 n = 8 %	**2017 n = 24 %**	2016 n = 6 %	**2017 n =11 %**	2016 n = 54 %	**2017 n = 57 %**
Increasing	0	**8**	17	**18**	4	**7**
Stable	50	**50**	67	**64**	46	**53**
Decreasing	38	**25**	0	**18**	39	**25**
Fluctuating	13	**17**	17	**-**	11	**16**

Note: Those choosing 'don't know' were excluded from analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.2.2 Methamphetamine purity

The most common purity rating was medium for speed (36%), medium for base (60%), and high for ice (35%) (Table15). The ratings for changes to purity/strength varied, but two-fifths of those who commented on ice (40%) rated purity as stable.

Table 15: Perceptions of methamphetamine purity in last six months, 2016 and 2017

	Speed		Base		Ice	
	2016 %	**2017 %**	2016 %	**2017 %**	2016 %	**2017 %**
Current purity/strength	n = 15	**n = 24**	n = 6	**n = 10**	n = 50	**n = 57**
High	27	**29**	17	**40**	48	**35**
Medium	53	**36**	17	**60**	36	**32**
Low	7	**21**	17	**0**	8	**26**
Fluctuates	13	**13**	50	**0**	8	**7**
Changes to purity/strength	n = 16	**n = 24**	n = 6	**n = 9**	n = 49	**n = 55**
Increasing	25	**17**	17	**22**	18	**13**
Stable	31	**33**	33	**67**	53	**40**
Decreasing	25	**33**	17	**0**	16	**27**
Fluctuating	19	**17**	33	**11**	12	**20**

Note: Those choosing 'don't know' were excluded from analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.2.3 Methamphetamine availability

The pattern of current availability was similar to 2016; although, small numbers for base make comparison difficult (Table 16). Just over half the respondents reported ice was very

easy/easy to obtain (53%). Availability were generally considered to be stable for all three forms (speed, base, and ice).

Table 16: Methamphetamine availability in last six months, 2016 and 2017

	Speed		Base		Ice	
	2016 %	**2017 %**	2016 %	**2017 %**	2016 %	**2017 %**
Current availability	n = 16	**n = 25**	n = 7	**n = 11**	n = 57	**n = 61**
Very easy	50	**36**	14	**18**	53	**53**
Easy	25	**40**	43	**27**	40	**38**
Difficult	19	**24**	29	**46**	5	**10**
Very difficult	6	**0**	14	**9**	2	**0**
Changes to availability	n = 16	**n = 25**	n = 7	**n = 25**	n = 55	**n = 61**
More difficult	19	**12**	29	**27**	6	**7**
Stable	75	**60**	71	**64**	76	**72**
Easier	6	**20**	0	**9**	16	**18**
Fluctuates	0	**8**	0	**0**	2	**3**

Note: Those choosing 'don't know' were excluded from analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.2.4 Amphetamine-type stimulants detected at the Australian border

The number and weight of detections of amphetamine-type stimulants (ATS) by the Australian Customs and Border Protection Service rose in the 2014–15 financial year, with 3479 seizures weighing a total of 3422 kilograms (Figure 25).

Figure 25: Weight and number of ATS* detections by the Australian Customs and Border Protection Service, 2004–05 to 2014–15



* includes amphetamine, methamphetamine and crystal methamphetamine detections, but excludes MDMA
Source: Australian Criminal Intelligence Commission, 2016

Of the 3,479 detections in the 2014–15 financial year, 2,615 were ice; and of the total weight of 3,422 kilograms, 1,721 kilograms were ice (ACIC, 2016). Figure 26 shows the steep rise in ice detections and weight of seizures in 2012–13 and the upward trend since then.

Figure 26: Weight and number of crystalline methamphetamine (ice) detections by the Australian Customs and Border Protection Service, 2004–05 to 2014–15



Source: Australian Criminal Intelligence Commission, 2016

5.2.5 Purchasing patterns of methamphetamines

A friend, known dealer, or acquaintance was the most likely source for the most recent purchase of all forms of methamphetamines (Table 17). The place of most recent purchase varied for all three forms of methamphetamines but, as in past years, an agreed public location was the most common.

Table 17: Purchasing patterns of methamphetamine, 2016 and 2017

	Speed		Base		Ice	
	2016 %	**2017 %**	2016 %	**2017 %**	2016 %	**2017 %**
Last purchased from	n = 16	**n = 24**	n = 6	**n = 10**	n = 56	**n = 59**
Street dealer	25	**13**	17	**20**	9	**7**
Friend	38	**29**	33	**40**	54	**36**
Known dealer	6	**21**	33	**30**	18	**32**
Acquaintance	25	**33**	17	**10**	16	**19**
Unknown dealer	6	**0**	0	**0**	4	**2**
Mobile dealer	0	**4**	0	**0**	0	**5**

	Speed		Base		Ice	
	2016 %	**2017 %**	2016 %	**2017 %**	2016 %	**2017 %**
Relative	0	**0**	0	**0**	0	**0**
Other	0	**0**	0	**0**	0	**0**
Place of most recent purchase	n = 16	**n = 22**	n = 6	**n = 10**	n = 55	**n = 58**
Home delivery	19	**18**	33	**10**	18	**14**
Dealer's home	0	**14**	17	**20**	2	**14**
Friend's home	19	**14**	0	**20**	26	**14**
Acquaintance's home	13	**9**	0	**0**	6	**7**
Street market	13	**0**	0	**10**	6	**5**
Agreed public location	38	**41**	50	**40**	42	**43**
Other	0	**5**	0	**0**	2	**3**

Source: Queensland IDRS PWID interviews

5.3 Cocaine market

KEY POINTS

- Only three participants reported on the cocaine market and their responses varied. Two commented on the price paid for a gram of cocaine: both paid $250.

Only three participants answered questions about the cocaine market. Their reports on purity, availability and price varied. Two commented on the price paid for a gram of cocaine: both paid $250.

5.3.1 Cocaine detected at the Australian border

Figure 27 shows the number and weight of cocaine detections at the border by the Australian Customs and Border Protection Service (ACBPS) in the 2014–15 financial year: 1781 seizures weighing a total of 369 kilograms.

Figure 27: Weight and number of cocaine border seizures by the Australian Customs and Border Protection Service, 2004–05 to 2014–15



Source: Australian Criminal Intelligence Commission, 2016

5.4 Cannabis market

KEY POINTS

- **Median price:** mostly reported as stable for both hydro and bush: a quarter ounce of hydro cost $90 and bush cost $70.
- **Potency:** generally rated as medium or high for both hydro and bush.
- **Availability:** hydro was readily available, and bush was half reported as readily available and half as difficult or very difficult.

Fourty-one per cent of the sample agreed they were able to distinguish between hydroponically cultivated cannabis (hydro) and outdoor-cultivated cannabis (bush). Thirty-six participants answered questions about the hydro market and 16 about the bush market.

5.4.1. Cannabis price

The median price of hydro and bush was:

Hydro

Gram	$22.50 (range $20-$25, n = 12)
Quarter ounce	$90 (range $50-$120, n = 17)
Half ounce	$180 (range $140-$250, n = 8)
Ounce	$290 (range $200-$400, n = 10)

Note: ^ Small numbers reported; interpret with caution (n <10)

Nearly all respondents (86%, n = 36) rated the price of hydro as stable.

Bush

Gram	$22.50 (range $15-$40, n = 4)
Three grams	$45 (range $40-$50, n = 2)
Quarter ounce	$70 (range $60-$100, n = 5)
Ounce	$290 (range $250-$360, n = 6)

Note: ^ Small numbers reported; interpret with caution (n <10)

Most respondents (80%, n = 15) rated the price of bush as stable.

5.4.2 Cannabis purity

The potency of hydro and bush was generally considered to be high or medium, with the majority reporting that potency had remained stable in the previous six months (Table 18).

Table 18: Perceived cannabis potency in last six months, 2016 and 2017

	Hydro		Bush	
	2016 %	**2017 %**	2016 %	**2017 %**
Current potency	n = 41	**n = 34**	n = 21	**n = 16**
High	68	**50**	10	**25**
Medium	24	**35**	81	**63**
Low	0	**3**	5	**13**
Fluctuates	7	**12**	5	**0**
Changes to potency	n = 38	**n = 35**	n = 20	**n = 15**
Increasing	11	**9**	0	**7**
Stable	74	**71**	70	**73**
Decreasing	0	**9**	15	**7**
Fluctuates	16	**11**	15	**13**

Note: Percentage totals may not equal 100 due to rounding. Source: Queensland IDRS PWID interviews

5.4.3 Cannabis availability

Table 19 shows that the current availability of hydro was mostly rated as easy or very easy, with most participants (75%) considering availability to be stable. There were mixed opinions about the availability of bush: with about half rating it easy or very easy and the other half rating it as difficult or very difficult. Most (73%) considered the bush market to be stable.

Table 19: Cannabis availability in last six months, 2016 and 2017

	Hydro		Bush	
	2016 %	**2017 %**	2016 %	**2017 %**
Current availability	n = 40	**n = 36**	n = 21	**n = 16**
Very easy	33	**42**	10	**25**
Easy	58	**33**	43	**25**
Difficult	8	**25**	38	**44**
Very difficult	3	**0**	10	**6**
Changes to availability	n = 41	**n = 36**	n = 21	**n = 15**
More difficult	15	**19**	14	**13**
Stable	73	**75**	81	**73**
Easier	10	**3**	5	**7**
Fluctuates	2	**3**	0	**7**

Note: Those choosing ‘don’t know’ were excluded from analysis. Percentage totals may not equal 100 due to rounding. Source: Queensland IDRS PWID interviews

5.4.4 Purchasing patterns of cannabis

As in previous years, a friend was the most likely source person for obtaining both hydro and bush (Table 20). A private home was the most likely place of purchase.

Table 20: Purchasing patterns of cannabis, 2016 and 2017

	Hydro		Bush	
	2016 %	**2017 %**	2016 %	**2017 %**
Last purchased from	n = 41	**n = 36**	n = 21	**n = 16**
Friend	56	**42**	52	**56**
Acquaitance	17	**11**	19	**13**
Known dealer	15	**36**	14	**25**
Street dealer	5	**8**	10	**6**
Relative	5	**3**	0	**0**
Unknown dealer	0	**0**	5	**0**
Workmate	0	**0**	0	**0**
Place of purchase	n = 41	**n = 35**	n = 21	**n = 16**
Friend's home	32	**26**	33	**44**
Agreed public location	15	**34**	24	**6**
Home delivery	27	**11**	14	**25**
Dealer's home	12	**20**	14	**13**
Street market	0	**3**	0	**6**
Acquaintance's home	12	**3**	14	**6**
Work	0	**0**	0	**0**
Other	0	**3**	0	**0**

Note: Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.4.5 Cannabis detections at the Australian border

The number of cannabis (includes cannabis leaf, oil, seed, and resin) detections at the border by the Australian Customs and Border Protection Service sharply increased in the 2014–15 financial year, but the total weight of seizures decreased from 158 kilograms in 2013–14 to 60 kilograms in 2014–15 (Figure 28).

Figure 28: Weight and number of cannabis border seizures by Australian Customs and Border Protection Service, 2004–05 to 2014–15



Source: Australian Criminal Intelligence Commission, 2016

5.5 Methadone market

KEY POINTS

- **Median price:** purchase quantity varied and numbers were too small for analysis
- **Availability:** generally easy to obtain
- **Purchasing pattern:** most likely to have been obtained from a friend or acquaintance.

Fifteen participants answered questions about the methadone market.

5.5.1 Methadone price

Ten respondents reported on the price of one millilitre of methadone: most all paid different amounts for their most recent purchase (range 0.00 to 1.25); 4 respondents paid $1.00. The one respondent who reported on the price of a 5mg physeptone tablet paid $5, and no one responded on the price of a 10 mg physeptone tablet.

Of the 15 respondents who reported on changes in price, ten considered price to be stable, three to be increasing, and two to be fluctuating.

5.5.2 Methadone availability

Nine of the 15 respondents reported that methadone was easy to obtain, two that it was very easy, and four that is was difficult. Thirteen of the 15 reported that availability was stable and two that it was more difficult.

5.5.3 Purchasing patterns of illicit methadone

Of the thirteen respondents who commented, seven sourced their most recent illicit methadone from a friend, four from an acquaintance, one from a known dealer, and one from an unknown dealer. Seven obtained the methadone at an agreed public location, three at a street market, two at a friend's home, and one at their own home (home deliverd).

5.6 Buprenorphine (Subutex®) market

KEY POINTS

- **Median price:** $40 for 8 mg tablet
- **Availability:** Over half (55%) of those who responded reported availablilty as difficult.
- **Purchasing pattern:** most commonly obtained from a friend. Source venue varied.

Twelve participants answered questions about the buprenorphine market.

5.6.1 Buprenorphine price

The median price of buprenorphine was:

2 mg $10^ (range $10–$10, n = 3)

8 mg $40^ (range $20–$50, n = 8)

Note: ^ Small numbers reported; interpret with caution (n <10)

Of the 12 respondents who commented, 9 reported that price was stable, 1 reported it was decreasing, and 1 reported it fluctuates.

5.6.2 Buprenorphine availability

Current availability of buprenorphine (n = 11) was mixed with almost half reporting it was easy (37%) or very easy (9%) and just over half reporting it was difficult (55%). There were no reports of it being very difficult. A little over half (55%, n = 11) reported that availability was stable with 9% reporting it was easier and 37% reporting it was more difficult.

5.6.3 Purchasing patterns of Buprenorphine

The source person for the most recent purchase (n = 9) was a friend (78%), street dealer (11%) or acquaintance (11%). Source venues were agreed public location (33%), home delivered (22%), friend's home (22.2%), street market (11%), and an aquaintance's home (11%).

5.7 Buprenorphine-naloxone (Suboxone®) market

KEY POINTS

- **Median price:** $20 for 8 mg film
- **Availability:** readily available
- **Purchasing patterns:** mainly purchased from a friend at a private home

Questions about the buprenorphine-naloxone market were answered by fifteen participants, for film only.

5.7.1 Buprenorphine-naloxone price

The median price of buprenorphine-naloxone film was:

2 mg $10^ (range $5–$10, n = 4)

8 mg $20^ (range $10–$40, n = 9)

Of the 15 respondents, 73% reported the price of film was stable; 13% reported it was decreasing, and 13% fluctuating.

Note: ^ Small numbers reported; interpret with caution (n <10)

5.7.2 Buprenorphine-naloxone availability

Most respondents (87%) reporting that Suboxone® film was readily available and 79% that availability was stable (Table 21).

Table 21: Availability of buprenorphine-naloxone film in last six months, 2016 and 2017

Ease of access	2016 % (n = 17)	**2017 % (n = 15)**	Changes to ease of access in last 6 months	2016 % (n = 15)	**2017 % (n = 14)**
Very easy	47	**47**	More difficult	0	**7**
Easy	41	**40**	Stable	88	**79**
Difficult	6	**13**	Easier	6	**14**
Very difficult	6	**0**	Fluctuates	6	**0**

Note: Those choosing 'don't know' were excluded from analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.7.3 Purchasing patterns of buprenorphine-naloxone film

Most (77%) of the 15 respondents made their most recent purchase of Suboxone® film from a friend at their friend's home; the others purchased from an acquaintance (15%) or street dealer (8%).

Purchases were made at an agreed public location (23%), home delivered (23%), friend's home (23%), an aquaintance's home (15%), street market (8%), or dealer's home (8%).

5.8 Morphine market

KEY POINTS

- **Median price:** 100 milligrams of MS Contin® (the most common purchase) was $50. Morphine prices were generally rated as stable.

  MS Contin® was the most commonly purchased brand, followed by Kapanol®.
- **Availability:** nearly three fifths of the respondents reported it as easy or very easy
- **Purchasing pattern:** just over half obtained from friends at a friend's home or an agreed public location

Twenty participants answered questions about the morphine market.

5.8.1 Morphine price

Participants were asked about the price of the specific brands of morphine (i.e. MS Contin® and Kapanol®) that they last purchased. The median prices were:

MS Contin	30 mg	$15^ (range $10–$20, n = 2)
	60 mg	$27.50^ (range $25–$30, n = 2)
	100 mg	$50 (range $15–$80, n = 13)
Kapanol	100 mg	$40^ (range $20–$60, n = 4)

Note: ^ Small numbers reported; interpret with caution (n <10)

Just over half the respondents considered price to be stable (56%).

5.8.2 Morphine availability

In 2017, participants who commented on the morphine market did not reach concensus on availability. Participants reported access was stable or becoming more difficult (Table 22).

Table 22: Availability of illicit morphine in last six months, 2016 and 2017

Ease of access	2016 % (n = 29)	**2017 % (n = 19)**	Changes to ease of access in last 6 months	2016 % (n = 28)	**2017 % (n = 19)**
Very easy	21	**26**	More difficult	11	**42**
Easy	52	**32**	Stable	82	**42**
Difficult	24	**37**	Easier	4	**11**
Very difficult	3	**5**	Fluctuates	4	**5**

Note: Those choosing 'don't know' were excluded from analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

5.8.3 Purchasing patterns of illicit morphine

Respondents (n = 18) last purchased morphine from a friend (56%), known dealer (28%), or street dealer (17%).

Venues for the most recent purchase of morphine (n = 18) were: an agreed public location (39%), a friend's home (33%), home delivered (11%), street market (11%), or dealer's home (6%).

5.9 Oxycodone market

KEY POINTS

- **Median price:** $40^ for 80 mg of Oxycontin Purdue® and $45^ for 80 mg of generic controlled-release oxycodone
- **Availability:** reports varied
- **Purchasing pattern:** The most common purchases were made from a friend. The source venues purchased from varied..

Eight participants answered questions about the oxycodone market.

5.9.1 Price

OP oxycodone (Oxycontin Purdue®)

Note: ^ Small numbers reported; interpret with caution (n <10)

Four participants reported on the OP oxycodone market: One reported their most recent purchase was 80 mg for a median price of $40^, two reported purchasing 40 mg for $15, and one participant reported purchasing 20 mg for $20.

Two considered the price was stable, and the other two considered the price as decreasing and fluctuating. Two reported access as easy and two as difficult.

Generic or other oxycodone

Four participants had purchased 80 mg of generic controlled-release oxycodone for a median price of $45^ (range $40–$50).

Of the seven participants who commented on the price of generic oxycodone, two rated it as increasing, two as stable, two as fluctuating, and one as decreasing.

5.9.2 Availability

Of the four participants who reported on availability for Oxycontin Purdue®, two reported it was difficult and two easy. Two of the four rated the market as more difficult, one as stable, and one as easier.

Of the eight participants who reported on availability for generic or other oxycodone, four reported it as difficult, three as easy, and one as very easy. Four of the eight considered the market as more difficult, two as stable, and two as easier.

Oxycontin Purdue® was purchased from a friend (two) or an acquaintance (one). All participants made the purchase at a private home. Generic or other oxycodone was purchased from friends (four), a street dealer (one), or an acquaintance (one). Two participants made the purchase at a friend's home, one at a dealer's home, one at a street market, and one at an agreed public location.

5.10 Benzodiazepine market

KEY POINTS

Reports on the benzodiazepine market should be treated with caution due to small numbers and little consensus.

10 participants answered questions about the benzodiazepine market.

5.10.1 Illicit benzodiazepine price

Median: $2 (range $1-$10, n = 7)

5.10.2 Illicit benzodiazepine availability

Of the ten participants who commented on availability, six considered it to be easy, two considered it to be very easy and two to be difficult.

5.10.3 Purchasing patterns of illicit benzodiazepine

Six participants had made their most recent purchase from a friend, two from an acquaintance, and one from a partner. Four of the nine participants purchased from an agreed public location, two from a friend's home, two home delivered, and one from a dealer's home.

5.11 Other drugs market

KEY POINTS

Reporting on the fentanyl market is limited due to small number of respondents.

5.11.1 Fentanyl market

Three participants reported on the fentanyl market.

One participant reported the price they last paid to be $75 and one reported $120. Two out of the three participants who responded said the price was stable and the other said increasing, and all three respondents reported the availability was stable. Two respondednts made their last purchase from a known dealer and one from a friend. The respondents each reported a different source venue: dealer's home, friend's home, and agreed public location.

6 HEALTH-RELATED TRENDS ASSOCIATED WITH DRUG USE

KEY POINTS

- **Overdose:** among participants who had ever used heroin (n = 91), nearly half (45%) had experienced an accidental overdose. Of these, 9% (nine participants) had overdosed in the preceding year. Very small numbers reported ever overdosing on morphine, methadone, or oxycodone.

  2% of participants had accidently overdosed on a drug other than heroin in their lifetime.
- **Treatment:** 57.3% of participants were currently in drug treatment, mainly opioid substitution therapy (OST).
- **Injecting risk:** nearly all participants had sourced needles from a Needle and Syringe Program (NSP) in the previous month.

  9% of participants had recently borrowed a used needle, and 11% had recently lent a used needle, with 19% reporting that they shared other equipment (predominantly spoons/mixing containers).

  One-in-three had re-used one of their own needles at least once in the previous month.
- **Mental health:** 44% of participants self-reported a mental health problem, with the most common problems being depression and anxiety.

  Half of the participants scored in the high distress or very high distress categories of the Kessler Psychological Distress Scale (K10).
- **Opioid dependence:** 61% of those who had recently used opioids had a score indicative of dependence.
- **Stimulant dependence:** 50% of those who had recently used stimulants had a score indicative of dependence (37 participants).
- **Naloxone:** just over three-quarters of participants had heard of naloxone, 37% had heard of the take-home program, and 25% were aware of the rescheduling.
- **Self-reported general health status**: one-in-four participants considered their general health to be very good or excellent, with the most common rating being good.

6.1 Overdose and drug-related fatalities

6.1.1 Heroin overdose

Among participants who had ever used heroin and commented (n = 91), 45% reported experiencing an accidental overdose. The median number of overdoses was four (range 1–40).

Of those who had overdosed (n = 46), 9% (nine participants) had done so in the previous 12 months. Three of the seven respondents reported receiving CPR from a friend, partner or peer and one from a health professional; three reported receiving Narcan; four reported that an ambulance attended; and three reported being admitted to an emergency department. Only one respondent reported later seeking out treatment/information as a result of the overdose: from a drug health service.

6.1.2 Morphine overdose

Of those who had ever used morphine and commented (n = 95), seven participants reported an accidental overdose. The median number of times was 1 (range 1–5, n = 7). None of these respondents reported overdosing on morphine in the previous 12 months.

6.1.3 Methadone overdose

Of those who had ever used methadone and commented (n = 96), three participants reported an accidental overdose once or twice. None of the respondents reported an overdose in the previous 12 months.

6.1.4 Oxycodone overdose

Of those who had ever used oxycodone and commented (n = 97), one participant reported an accidental overdose five times, and did not report a recent overdose.

6.1.5 Other drugs overdose

Of the entire sample (n = 100), 16% reported an accidental overdose on any other drug. The median number of other overdoses was 1.50 (n = 16, range 1–10). Five respondents had overdosed in the previous 12 months, and two of these in the previous month. Among these five respondents, there was no common overdose substance: fentanyl, benzodiazepine, and ice.

6.2 Drug treatment

6.2.1 Current drug treatment

Over half of the sample reported being in treatment, with methadone continuing to be the most common form of treatment (Figure 30). The median time in current treatment was 18 months (n = 56, range 1 month–300 months).

Figure 29: Current treatment status, 2016 and 2017



Source: Queensland IDRS PWID interviews

Figure 31 shows the forms of treatment that participants had been in over the preceding six months, with an increase in Suboxone treatment over 2016 reports

Figure 30: Forms of treatment received in last six months, 2016 and 2017



Note: Multiple responses allowed
Source: Queensland IDRS PWID interviews

Opioid treatment

Among all participants, 53% had participated in some form of opioid substitution treatment in the previous year. The median number of times these participants had begun opioid treatment in the past year was one (range 0-1 times).

Methamphetamine treatment

Nine participants had participated in methamphetamine treatment in the previous year. Only two of these participants had started treatment twice and seven only once. Five had been admitted to hospital in the past year: four for psychosis and the other did not specify.

Barriers to treatment

Sixteen per cent of participants reported they had tried to access treatment in the last six months but were turned away. These 16 participants were seeking treatment for problems with the following drugs:methamphetamine (n = 6), heroin (n = 4), methadone (n = 2), alcohol (n = 1), and cannabis (n = 1). The services they tried to access were: rehab/therapeutic community (n = 6), detox (n = 3), opioid substitution program (n = 5), counsellor (n = 3), psychologist (n = 3), opioid substitution doctor (n = 3), and GP (n = 2).

Table 23 shows participants' perception of how easy it is to get drug treatment. Nearly half reported it as easy (44%) and fewer than one in five (18%)described it as difficult.

Table 23: Perception of current access to drug treatment, 2016 and 2017

	2016 % n = 81	**2017** **%** **n = 103**
Very easy	11	**19**
Easy	43	**44**
Difficult	35	**18**
Very difficult	11	**10**

Note: 'don't know' responses were excluded from this analysis. Percentage totals may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

6.2.2 Drug treatment agencies

In 2014–15, there were 181 publicly funded alcohol and other drug treatment agencies in Queensland, which provided treatment to 31 958 clients (AIHW 2016). Treatment has a broad definition which includes information and education only; but about a third of clients received counselling.

Estimated number of pharmacotherapy clients in 2015

In Queensland, the estimated number of pharmacotherapy clients in was stable with 6,418 clients (13 per 10,000 population) receiving pharmacotherapy treatment on a 'snapshot'/specified day in June 2015 (aihw.gov.au). Of these, 48% were receiving

methadone, 12% were receiving buprenorphine (Subutex®), and 40% were receiving buprenorphine-naloxone (Suboxone®). The proportions were similar to those in recent years.

Three-in-five clients were male. The median age was 41 years, with the median age for methadone being 43 years, buprenorphine 39 years, and buprenorphine-naloxone 39 years.

There were 551 dosing sites in Queensland in 2014 (537 in 2014), and these were most commonly pharmacies (68%, 81% in 2014). The number of prescribers registered to prescribe pharmacotherapy drugs in 2015 was 196 (221 in 2014).

6.3 Injecting risk behaviour

6.3.1 Access to needles and syringes

As in previous years, needle and syringe programs (NSP) were overwhelmingly the most common venue for acquiring needles and syringes (Figure 36). However, this is to be expected, given our sample was largely recruited from NSP sites.

Figure 31: Source of needles and syringes in last month, 2017



Note: Multiple responses allowed.
Source: Queensland IDRS PWID interviews

Only six per cent of participants reported that they had trouble getting needles and syringes when they needed them in the last month; and 8% reported that they had trouble getting filters when they needed them.

In the financial year 2015–16, the Queensland Health NSP reported supplying a total of 10,835,495 syringes/sharps: 8,755,255 to their NSP programs, 1,876,225 to pharmacy NSPs, and 204,015 to private pharmacies.

Information about injecting and obtaining needles and syringes is provided in Table 24. More needles and syringes were obtained than needed for personal use.

Table 24: Injecting and obtaining needles and syringes in the last month, 2017

n = ~89	Mean	Median	Range
Approximate times injected	40	20	0-720
Times got needles and syringes	4	2	0–30
Total number of new needle and syringes obtained	95	63	0–600
Needles and syringes obtained for self most recent time	48	25	0–390
Syringes given away or sold	27	10	0–510
Syringes stored away	24	10	0–500

Source: Queensland IDRS PWID interviews

6.3.2 Sharing of injecting equipment

As Figure 37 shows, the reports of sharing injecting equipment in the past month have been relatively low and stable in recent years: 9% of participants borrowed a used needle, 11%

lent a used needle, and 19% shared other equipment (e.g. spoons or mixing containers, filters, tourniquets, water, swabs).

Six of the seven participants who had borrowed a used needle in the past month reported on who they had borrowed from: three borrowed from their regular sex partner, three from a close friend, and two from an aquaintance. Four of the 9 respondents reported borrowing one time, two reported two times, two three-to-five times, and one ore than ten times. Six reported that one person had used a needle before them, one reported two people had, and one reported three-to-five people had.

Figure 32: Borrowing and loaning of needles and other equipment in the last month, 2007 to 2017



Source: Queensland IDRS PWID interviews

As in recent years, nearly tone-third (31%) re-used one of their own needles at least once in the previous month. The median number of times was 0 (range 0–5, n = 31).

In regard to re-use of other equipment, spoons/mixing containers remained the items most commonly re-used, whether they were participants' own or someone else's (Table 25).

Table 25: Other equipment re-used in the last month, 2016 and 2017

Other equipment	Other equipment re-used			
	Own		After someone else	
	2016 (n = 56) %	**2017 (n = 51) %**	2016 (n = 19) %	**2017 (n = 20) %**
Spoons/mixing containers	82	**73**	79	**75**
Filters	4	**14**	26	**35**
Tourniquets	32	**47**	16	**60**
Water	13	**16**	37	**40**
Swabs	2	**8**	0	**30**
Wheel filter	4	**10**	5	**15**
Other	2	**0**	0	**5**

Note: Multiple responses allowed.
Source: Queensland IDRS PWID interviews

The use and re-use of injecting equipment followed a similar pattern to previous years, with the 1 ml needle and syringe continuing to be the most common piece of injecting equipment, and the piece of equipment most commonly re-used (Table 26).

Table 26: Use and re-use of injecting equipment in the last month, 2016 and 2017

	Used in last month		Re-used in last month	
	2016 n = 90 %	**2017 n = 97 %**	2016 n = 90 %	**2017 n = 98 %**
0.5 ml needle and syringe	0	**1**	1	**1**
1 ml needle and syringe	81	**78**	36	**29**
3 ml syringe (barrel)	30	**21**	3	**5**
5 ml syringe (barrel)	14	**8**	1	**1**
10 ml syringe (barrel)	11	**12**	1	**4**
20 ml syringe (barrel)	8	**14**	1	**4**
Detachable needle (tip)	10	**21**	1	**5**
Winged vein infusion set (butterfly)	20	**25**	2	**5**
Wheel filter	6	**7**	0	**5**
Commercial cotton filter	10	**45**	0	**7**

Note: Multiple responses allowed.
Source: Queensland IDRS PWID interviews

Lending needles in the last month

In the last month:

- 25% of participants reported that, after injecting themselves, they injected a partner or friend with a new needle.
- 18% reported that they were injected with a new needle by somebody who had already injected themselves/others.
- 1% reported that they were injected with both a new and used needle by somebody who had already injected themselves others.

6.3.3 Injection site, and location

The site of participants' most recent injection was generally the arm (68%), followed by hand/wrist (12%), neck (8%), leg (3%), foot (2%), groin (2%), and other (1%). Participants' most recent injection was commonly in a private home (Figure 38).

Figure 33: Location where participant last injected, 2016 and 2017



Source: Queensland IDRS PWID interviews

6.3.4 Injection-related issues

The most common injection-related issue was scarring and/or bruising (52%)—an issue that has become more common in recent years (Table 27). Difficulty injecting (44%) was also a common issue.

Of those who experienced a dirty hit in the previous month (n = 15), the drugs reported varied: Subutex (4%), Methamphetamine (3%), Heroin (3%), Methadone (3%), and Suboxone (2%).

Three of the four participants who experienced an overdose in the previous month reported that the main drug involved was heroin and one reported methamphetamine.

Table 27: Injection-related issues experienced in the last month[a], 2008 to 2017

	2008	2009	2010	2011	2012	2013	2014	2015	2016	**2017**
	%	%	%	%	%	%	%	%	%	**%**
Difficulty injecting	38	38	30	49	53	68	63	81	82	**44**
Scarring/bruising	46	64	41	80	60	60	57	69	73	**52**
Dirty hit	20	31	11	13	23	21	24	12	11	**15**
Abscess/infection	8	15	8	13	12	15	2	9	16	**10**
Thrombosis	4	9	4	2	14	8	8	9	7	**4**
Overdose	3	1	2	0	2	2	8	2	7	**4**

[a] Amongst those who experienced an injection-related issue
Note: Multiple responses allowed.
Source: Queensland IDRS injecting drug user interviews

6.4 Opioid and stimulant dependence

Understanding whether participants are dependent on a drug type is an important predictor of harm, and typically demonstrates stronger relationships than simple frequency of use measures. Thus the participants were asked questions from the Severity of Dependence Scale (SDS) for the use of stimulants and opioids.

The SDS is a five-item questionnaire designed to measure the degree of dependence on a variety of drugs. The SDS focuses on the psychological aspects of dependence, including impaired control of drug use, and preoccupation with, and anxiety about, use. The SDS appears to be a reliable measure of the dependence construct. It has demonstrated good psychometric properties with heroin, cocaine, amphetamine, and methadone maintenance patients across five samples in Sydney and London (Dawe, Loxton, Hides et al., 2002).

Previous research has suggested that a cut-off value of four is indicative of dependence for methamphetamine users (Topp & Mattick, 1997), and a cut-off value of three for cocaine users (Kaye & Darke, 2002). No validated cut-off for opioid dependence exists; however, researchers typically use a cut-off value of five for the presence of dependence.

Opioids

Of those who had recently used an opioid and commented (n = 77), the median SDS score was six (mean = 6, range 0–15), with 61% scoring five or above.. Of those who scored five or above (n = 50), 9% reported no specific opioid used the most, 30% specified heroin, 4% buprenorphine, 10% morphine, 16% methadone, 4% specified an unlisted opioid, and 3% oxycodone.

Stimulants

Of those who had recently used a stimulant and commented (n = 71), the median SDS score was four (mean = 4, range 0–15), with 50% scoring four or above. Of those who scored four or above (n = 37), all specified that their responses were about methamphetamines.

6.5 Mental health problems, psychological distress, and general health

More than two in five participants reported a mental health problem (Figure 39), with depression and anxiety continuing to be the two most common problems (Table 28).

Figure 34: Self-reported mental health problem, 2009 to 2017



Source: Queensland IDRS PWID interviews

Table 28: Mental health in last six months, 2016 and 2017

	2016 N = 75 %	**2017** **N = 91** **%**
Self-reported mental health problem	59	**44**
Problems reported	(n = 44)	**(n = 45)**
Depression	55	**53**
Anxiety	39	**64**
Post-traumatic stress disorder	23	**38**
Manic-depression/bipolar	14	**16**
Schizophrenia	9	**4**
Drug induced psychosis	9	**9**
Mania	9	**0**
Phobias	7	**2**
Panic	5	**13**
Obsessive-compulsive disorder	2	**2**
Paranoia	2	**7**
Any personality disorder	0	**9**
Other	16	**0**

Note: Multiple responses allowed
Source: Queensland IDRS PWID interviews

Of those participants who reported a mental health problem (n = 45), 62% had attended a health professional for their mental health problem in the previous six months (Table 29). As in previous years, a GP was the most commonly visited health professional.

Table 29: Mental health professional attended in last six months, 2017

Participants with self-reported mental health problem	n = 44 %
Attended mental health professional in last six months	62
	n = 45 %
GP	57
Psychologist	18
Counsellor	11
Psychiatrist	25
Mental health nurse	18
Psychiatric-ward health professional	7
Social worker	14

Note: Multiple responses allowed
Source: Queensland IDRS PWID interviews

Of those participants with a self-reported mental health problem (n = 45), 62% had been prescribed one or more medications in the previous six months (Table 30). Anti-depressants were the most common medication prescribed, with Valium® being the most common brand.

Table 30: Medication prescribed for a mental health problem in last six months, 2017

Participants with self-reported mental health problem	n = 45 %
Prescribed a medication in the last six months	62
	n = 28 %
Anti-depressants (e.g. Lexapro®)	43
Benzodiazepines (e.g. Valium®)	64
Anti-psychotics (e.g. Seroquel®)	36
Mood stabiliser	4

Note: Multiple responses allowed
Source: Queensland IDRS PWID interviews

The Kessler Scale of Psychological Distress (K10)

The Kessler Scale of Psychological Distress (K10) was administered. This is a 10-item standardised measure that has been found to have good psychometric properties and to identify clinical levels of psychological distress as measured by the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) and the Structured Clinical Interview for DSM disorders (SCID) (Andrews & Slade, 2001; Kessler et al., 2002).

K10 scores reflecting 'risk' are often categorised as follows: 'low'—the person is likely to be well (scores 10–15); 'moderate'—the person may have a mild mental disorder (scores 16–20); 'high'— the person is likely to have a moderate mental disorder (scores 22–29); and

'very high'—the person is likely to have a severe mental disorder (scores 30–50). The 2013 National Drug Strategy Household Survey (NDSHS) (AIHW, 2014) provided the most recent Australian population norms for the K10.

As shown in Table 31, levels of psychological distress in 2017 were similar to 2016, with participants vastly more likely to score high distress or very high distress than the general population (18 years and over) in the 2016 NDSHS (10% among non drug users and 23% among those having used any illicit drug in the last 12 months).

Table 31: K10 scores, 2016 and 2017

K10 score	Level of psychological distress	2016 n = 85 %	2017 n = 88 %
10–15	No/low distress	21	**22**
16–21	Moderate distress	28	**20**
22–29	High distress	25	**32**
30–50	Very high distress	26	**26**

Note: the extent to which cut-offs derived from population samples can be applied to the IDRS population is yet to be established and, therefore, these findings should be taken as a guide only.
Source: Queensland IDRS PWID interviews; AIHW 2017

Thirty six per cent of participants rated their general health as poor or fair, with similar proportions (38%) rating their health as good (Figure 40).

Figure 35: Self-reported general health status, 2017



n = 101

Note: The percentage total may not equal 100 due to rounding.
Source: Queensland IDRS PWID interviews

6.7 Naloxone program and distribution

Naloxone is a short-acting opioid antagonist that has been used for over 40 years to block the effects of opioids. It is the frontline medication for the reversal of heroin and other opioid overdoses. In Australia, use of naloxone for the reversal of opioid effects has been limited to medical doctors (or those authorised by medical doctors such as nurses and paramedics). In 2012, a take-home naloxone program commenced in the Australian Capital Territory as part of a comprehensive overdose-response package. The program made naloxone available to peers and family members of PWID. Shortly after, similar programs commenced in other states. In early 2016, naloxone was rescheduled to allow over-the-counter supply without a prescription.

Since 2013, a series of questions have been asked about take-home naloxone programs and naloxone more broadly. Three-quarters of those who commented had heard of naloxone; among these respondents, four-in-five reported that naloxone was used to 'reverse heroin.'

Just over one-third of participants (37%) had heard of the take home scheme, with 6% participating. One quarter (25%) had heard about the rescheduling, with 7% having accessed over-the-counter naloxone.

Over half of the participants (59%) reported that they would be willing to purchase naloxone over the counter, 30% would be willing ot carry it on their person, 53% would be willing to administer naloxone after an overdose, and 52% would be willing to stay with someone after giving them naloxone (Table 32).

Table 32: Knowledge about take-home naloxone program, 2016 and 2017

	2016 n = 83 %	2017 n = 95 %
Heard of naloxone	87	**77**
Naloxone description	n = 69	**n = 78**
Reverses heroin	62	**73**
Helps start breathing	25	**24**
Re-establishes consciousness	25	**43**
Other	30	**11**
Heard of the take-home naloxone program	n = 83	**n = 94**
Yes	36	**37**
No	64	**54**
Heard of the rescheduling of naloxone	**n/a**	**n=95**
Yes	-	**25**
Willing to purchase naloxone	-	**59**
Willing to administer naloxone	-	**53**

Note: Multiple responses allowed. Source: Queensland IDRS PWID interviews

In 2017, 5% of participants reported having been resuscitated with Narcan®/naloxone by someone trained through a take-home naloxone program.

Six participants (6%) had been through a course and received a prescription for Narcan®/naloxone: three had used the Narcan®/naloxone to resuscitate, or attempt to resuscitate, someone who had overdosed.

6.8 Driving risk behaviour

Of those who had driven in the past six months (n = 39), 10% reported driving while over the legal limit of alcohol; one person reported 10 occasions (the others were fewer). Seventeen participants reported having been breath tested; only one result was positive.

Two-thirds (67%) reported driving within three hours (a median of 30 minutes) of taking illicit or non-prescribed drugs, and a median number of 20 times with five participants reporting doing this daily. Only twelve of these participants reported a road side drug test; four of these were positive with cannabis (n = 3), amphetamines (n = 1), and opiates (n = 2) being detected.

Table 33: Drugs used before driving, 2017

	Last 6 months (n = 26) %	Last occasion (n = 26) %
Heroin	50	46
Methadone	15	4
Suboxone	4	0
Morphine	4	4
Speed	4	0
Ice	31	31
Cannabis	12	12
Benzodiazapines	12	15
Other opiates	4	0

Note: Multiple responses allowed.
Source: Queensland IDRS PWID interviews

7 LAW ENFORCEMENT-RELATED TRENDS ASSOCIATED WITH DRUG USE

KEY POINTS

- **Criminal involvement reported in the last month:** 50%. As in previous years, dealing was the most often reported criminal activity (31%) followed by property crime (30%).
- **Arrested in the last 12 months:** 40%. The most common reason was use/possession of drugs.
- **Money spent on illicit drugs:** 47% of the sample reported spending money on illicit drugs the day before (range $0 to $455).

7.1 Prison history

Over half of all participants (58%) had been in prison. This was a simiiar proportion to previous years (e.g. 55% in 2016).

7.2 Reports of criminal activity

The pattern of self-reported criminal activity has been relatively stable over the last decade, with dealing and property crime most commonly reported(Figure 41). In 2017, a half of all participants (50%) reported recent criminal activity.

Figure 36: Prevalence of criminal involvement in previous month, 2007 to 2017



Note: Multiple responses allowed.
Source: Queensland IDRS PWID interviews

Nearly one in five (18%) of all participants reported that they had been a victim of a crime involving violence in the previous month.

7.3 Arrests

Forty-four per cent of all participants reported being arrested in the last 12 months (38% in 2015). Nearly a half of those arrested (45%) reported being arrested for use/possession of drugs (Figure 42).

Figure 37: Main reasons for arrest in last 12 months, 2016 and 2017



Note: Multiple responses allowed
Source: Queensland IDRS PWID interviews

Table 34 presents the most recent available data for drug-related arrests made by the Queensland Police Service (ACIC 2016). In 2014–15 there was a similar pattern of arrests to recent years, with the majority of arrests related to cannabis (59%), followed by amphetamine-type stimulants (24%). There were a total of 40 404 arrests compared with 32 391 in 2013–14. Data for 2015–16 were unavailable at the time of publication.

Table 34: Drug-related arrests by Queensland Police Service, by drug type, 2014–15

	Consumer	Provider	Total
Cannabis	21 211	2639	23 850
Amphetamine-type stimulants[a]	8462	1071	9533
Other and unknown	4690	658	5348
Steroids	573	129	702
Heroin and other opioids	284	29	313
Hallucinogens	215	50	265
Cocaine	317	76	393
Total	**35 752**	**4652**	**40 404**

[a] includes amphetamine, methylamphetamine, and phenethylamines
Note: consumer = use, possession or administering for own use; provider = importation, trafficking, selling, cultivation and manufacture.
Source: Australian Criminal Intelligence Commission, 2016

Table 35 shows the number of seizures by the Queensland Police Service and the Australian Federal Police for each drug type along with their weight (ACIC 2016). Data for 2015–16 were unavailable at the time of publication.

Table 35: Queensland drug seizures, by police service and drug type, 2014–15

	Police force	No. of seizures	Weight (grams)
Cannabis	QPS	17 305	818 119
	AFP	227	14 500
Amphetamine-type stimulant	QPS	6268	45 545
	AFP	459	146 306
Heroin	QPS	209	1226
	AFP	11	4552
Other opioids	QPS	3	0
	AFP	9	5152
Cocaine	QPS	251	3659
	AFP	164	56 741
Steroids	QPS	124	5733
	AFP	12	10 568
Hallucinogens	QPS	29	604
	AFP	31	742
Other and unknown drugs	QPS	870	28 831
	AFP	269	76 716

Note: Includes only those seizures for which a drug weight was recorded. No adjustment has been made for double counting data from joint operations between the Australian Federal Police and Queensland Police Service.
Source: Australian Ciminal Intelligence Commission, 2016

Nationally, a total of 667 clandestine labs were detected in the 2014–15 financial year (744 in 2013–14) (ACIC 2016). In Queensland there were 236 detections, with nearly half of the substances at the detections unkown/awaiting analysis (47%) and 43% being an amphetamine-type stimulant (ATS; excluding MDMA) lab (Figure 43). Most of the detections in Queensland continued to be addict-based labs. Data for 2015–16 were unavailable at the time of publication.

Figure 38: Clandestine labs seized in Queensland from 2005–06 to 2014–15



Source: Australian Criminal Intelligence Commission, 2016

7.4 Expenditure on illicit drugs

Forty-seven per cent of the sample reported spending money on illicit drugs the previous day (44% in 2016). A break-down of expenditure is shown in Table 36, with the most common range being $100 to $199.

Table 36: Expenditure on illicit drugs on previous day, 2010 to 2017

Expenditure	2010 N = 99 %	2011 N = 102 %	2012 N = 94 %	2013 N = 99 %	2014 N = 100 %	2015 N = 98 %	2016 N = 91 %	**2017 N = 100 %**
Nothing	44	46	46	48	57	44	56	**53**
Less than $20	0	2	3	4	1	1	3	**7**
$20 to $49	8	11	10	11	4	5	8	**5**
$50 to $99	14	13	18	14	7	11	15	**13**
$100 to $199	16	20	10	15	18	20	8	**17**
$200 to $399	10	6	11	6	7	11	9	**4**
$400 or more	7	2	3	2	5	7	1	**2**
Median expenditure	$100	$100	$70	$77.5	127.50	100	55	**0**

Source: Queensland IDRS PWID interviews

8 SPECIAL TOPICS OF INTEREST

KEY POINTS

- **Blood donations:** 12% reported giving blood in their lifetime. No one reported giving blood soon after injecting.
- **Unfair treatment and resilience:** 25% reported never being unfairly treated, but 16% reported experiencing this daily. Females tended to score higher on the resilience scale than males. .

8.1 Blood donations

In Australia and most other territories around the world (excluding Japan), people with a history of injecting drug use comprise a 'risk group' who are permanently excluded from donating blood and blood products due to the high risk of infection from BBV and sexually transmitted virus such as HCV and HIV (regardless of past injecting drug use 'remoteness' and current BBVI status).

In 2014 the Australian Red Cross Blood Service commissioned the Burnet Institute to conduct a review of international literature and guidelines to evaluate the appropriateness of their current eligibility criteria around blood donation and injecting drug use. One of the review's main outcomes was the paucity of data on prevalence of lifetime blood donation among PWID, which precludes calculations of estimates of the risk associated with changing the exclusion/deferral period from permanent to a reduced timeframe (e.g. five years).

Of those who commented (n = 82), 12% reported that they had given blood in their lifetime (18% in 2015). Four of these ten respondents had commenced injecting drug use before donating blood. Three of the four participants commented on how long before most recently giving blood they had injected: one had injected seven days before, and other two had last injected three years before.

8.2 Unfair treatment and resilience

Being discriminated against is a common event for PWID, particularly those who inject drugs. The IDRS provided an opportunity to obtain important insights into the multiple origins and impacts of unfair treatment against PWID. The questions included in the 2017 IDRS aimed to clarify the relationships between unfair treatment and the resilience of participants, as well as help to inform policy and improve the quality of services. The 'unfair treatment' question is based on previous 2013 IDRS questions, developed in conjunction with the Australian Injecting and Illicit Drug Users League (AIVL) (Stafford and Burns, 2014), and two validated and well-accepted scales.

In 2017, 25% of those who commented (n = 102) reported that they had 'never' been unfairly treated, and 11% reported that they had not experienced unfair treatment in the last 12 months. However, 30% did report unfair treatment 'monthly', 19% 'weekly but not daily' and 16% experienced unfair treatment 'daily or more' (Table 37) These figures are consistent with 2016 findings.

Table 37: Unfair treatment experienced by PWID, 2016 and 2017

Participant reports of unfair treatment	2016 n = 87 %	**2017 N=102 %**
Treated unfairly		
Never	22	25
Not in the last 12 months	17	11
Monthly	29	30
Weekly, but not daily	21	19
Daily or more	12	16

Source: Queensland IDRS PWID interviews

The Brief Resilience Scale (BRS) uses six items to assess resilience, generating a resilience score between 1 and 6, where a higher score indicates greater resilience. The BRS has been successfully validated in several health studies (Smith et al, 2008) and provides a measure of the ability of IDRS participants to cope with adversity. The mean score for 2017 participants was 3.35 (SD 0.73), with females being more resilient than males (scores of 3.61 and 3.26 respectively, $p<0.05$) and more males than females reporting low resilience (Table 38).

Table 38: Resilience of PWID, 2017

	Males (n=74)	**Females (n=25)**	**All participants (n=99)**
Total score (SD)	3.26 (0.72)	3.61 (0.70)	3.35 (0.73)
Low resilience (score≤2)	6%	0	5%
Moderate resilience (score 2-4)	66%	52%	63%
High resilience (score ≥4)	27%	48%	32%

Source: Queensland IDRS PWID interviews

REFERENCES

American Psychiatric Association (2013). *Diagnostic and Statistical Manual for Mental Disorders (Fifth edition),* Washington, DC, American Psychiatric Association.

Andrews, G. & Slade, T. (2001). Interpreting scores on the Kessler Psychological Distress Scale (K10). *Australian and New Zealand Journal of Public Health, 25*, 494–497.

Australian Bureau of Statistics. (1995). *National Health Survey SF-36, Population Norms Australia*. Canberra: ABS.

Australian Bureau of Statistics. (2012). *Australian Bureau of Statistics Census of Population and Housing, Estimating Homelessness, 2011*. Canberra: ABS.

Australian Criminal Intelligence Commission. (2016). Illicit Drug Data Report 2014–15. Canberra, ACIC, Commonwealth of Australia.

AIHW. (2014). National Drug Strategy Household Survey, Detailed Rreport 2013. Drug Statistics Series 28 Cat no. PHE 183. Canberra: Australian Institue of Health and Welfare.

AIHW. *National Opioid Pharmacotherapy Statistics (NOPSAD) 2015*. aihw.gov.au

Bush, K., Kivlahan, D.R., McDonell, M.B., Fihn, S.D., & Bradley, K. A. (1998). The AUDIT Alcohol Consumption Questions (AUDIT-C). *Arch Intern Med, 158*, 1789–1795.

Coffin, P.O., Tracy, M., Bucciarelli, A., Ompad, D.C., Vlahov, D., & Galea, S. (2007). Identifying Injection Drug Users at Risk of Nonfatal Overdose. *Academic Emergency Medicine, 14(7)*, 616–623.

Darke, S. (1994). The use of benzodiazepines among injecting drug users. *Drug and Alcohol Review, 13,* 63–69.

Darke, S., Duflou, J., & Kaye, S. (2007). Comparative toxicology of fatal heroin overdose cases and morphine positive homicide victims. *Addiction, 102*, 1793–1797.

Darke, S., Ross, J. & Hall, W. (1996) Overdose among heroin users in Sydney, Australia: Prevalence and correlates of non-fatal overdose. *Addiction,* 91**,** 405–411.

Dawe, S., Loxton, N. J., Hides, L., Kavanagh, D. J. & Mattick, R. P. (2002) *Review of Diagnostic Screening Instruments for Alcohol and Other Drug Use and Other Psychiatric Disorders*. Canberra, Commonwealth Department of Health and Ageing.

Dawson, D.A., Grant, B.F., Stinson, F.S., & Zhou, Y. (2005). Effectiveness of the Derived Alcohol Use Disorders Identification Test (AUDIT-C) in screening for alcohol use disorders and risky drinking in the US general population. *Alcoholism: Clinical and Experimental Research, 29(5)*, 844–854.

Fazel, S., Khosla, V., Doll, H., & Geddes, J.(2008). The prevalence of mental disorders among the homeless in western countries: Systematic review and meta-regression analysis. *PLoS Medicine 5*, e225.

Haber, P., Lintzeris, N., Proude, E., & Lopatko, O. (2009). *Guidelines for the Treatment of Alcohol Problems*. Canberra: Australian Government Department of Health and Ageing.

International Wellbeing Group (2013). *Personal Wellbeing Index: 5th edition*. Melbourne: Australian Centre on Quality of Life, Deakin University.

Iversen, J., Chow, L., & Maher, L. (2014) *Australian Needle and Syringe Program National Data Report 2009–2013*. The Kirby Institute, University of New South Wales.

Iversen, J. and Maher, L. (2015). *Australian Needle and Syringe Program National Data Report 1995–2014*.The Kirby Institute, University of New South Wales.

Kaye, S. & Darke, S. (2002). Determining a diagnostic cut-off on the Severity of Dependence Scale (SDS) for cocaine dependence. *Addiction, 97*, 727–731.

Kessler, R.C., Andrews, G., Colpe, L.J., Hiripi, E., Mroczek, D.K., Normand, S.L.T., . . . Zaslavsky, A.M. (2002). Short screening scales to monitor population prevalences and trends in non-specific psychological distress. *Psychological Medicine, 32*, 959–976.

Queensland Health (2016) *Queensland Minimum Data Set for Needle and Syringe Programs 2015.* Brisbane, State of Queensland (Queensland Health).

Roxburgh, A & Burns, L (2014) *Accidental drug-induced deaths due to opioids in Australia, 2011*. Sydney, National Drug and Alcohol Research Centre.

Roxburgh, A. & Breen, C. (2017) *Drug-related hospital stays in Australia 1993–2014*. Sydney, National Drug and Alcohol Research Centre.

Schiff, E.R., & Ozden, N. (2004). *Hepatitis C and Alcohol Publications*. Bethesda: National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health.

Smith, B.W., et al. (2008). The brief resilience scale: Assessing the ability to bounce back, *International Journal of Behavioral Medicine*. 15(3): p. 194-200.

Stafford, J. and Burns, L. (2014). *Australian Drug Trends 2013: Findings from the Illicit Drug Reporting System (IDRS)*. Australian Drug Trends Series. no.109. Sydney, National Drug and Alcohol Research Centre, University of New South Wales.

Topp, L. & Mattick, R. (1997). Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. *Addiction*, *92*, 839–845.

Thornicroft, G., Brohan, E., Rose, D., Sartorius, N., Leese, M., & The INDIGO Study Group (2009). Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey, *The Lancet***,** vol. 373, no. 9661, pp. 408–415.